



A



13



ng nodes :

1 2 3 4 5 6 7 8 9 10 11 12

ng/chain nodes :

13

ng bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 7-10 8-9 9-12 10-11 11-12

act/norm bonds :



5-7 6-9 7-8 7-10 8-9 9-12 10-11 11-12

rmalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

tch level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:CLASS



ng nodes :

1 2 3 4 5 6 7 8 9 10 11 12

ng bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 7-10 8-9 9-12 10-11 11-12

act/norm bonds :

5-7 6-9 7-8 7-10 8-9 9-12 10-11 11-12

rmalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

tch level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom

12:Atom

Aryl Fused Azapolycyclic Compounds

=> d his

(FILE 'HOME' ENTERED AT 14:38:57 ON 14 MAY 2004)

FILE 'REGISTRY' ENTERED AT 14:39:09 ON 14 MAY 2004

L1 STRUCTURE UPLOADED
L2 QUE L1
L3 1 S L2
L4 100 S 230615?/RN
L5 578891 S 5-6-6/SZ
L6 105840 S 5-5-6-6/SZ
L7 384378 S 5-6-6-6/SZ
L8 4152 S 4-5-6-6/SZ
L9 22481 S 5-6-6-7/SZ
L10 65762 S 5-5-6-6-6/SZ
L11 1158175 S L5 OR L6 OR L7 OR L8 OR L9 OR L10
L12 2 S L2 SUB=L11 SAM
L13 366 S L2 SUB=L11 FUL

FILE 'CAPLUS' ENTERED AT 14:47:17 ON 14 MAY 2004

L14 23 S L13

FILE 'REGISTRY' ENTERED AT 14:47:39 ON 14 MAY 2004

FILE 'CAOLD' ENTERED AT 14:48:24 ON 14 MAY 2004
L15 0 S L13

FILE 'CAPLUS' ENTERED AT 14:48:31 ON 14 MAY 2004

FILE 'REGISTRY' ENTERED AT 14:49:37 ON 14 MAY 2004
L16 STRUCTURE UPLOADED
L17 QUE L16
L18 2 S L17 SUB=L11 SAM
L19 370 S L17 SUB=L11 FUL
L20 4 S L19 NOT L13

FILE 'CAPLUS' ENTERED AT 14:50:49 ON 14 MAY 2004


L21 14 S L20
L22 23 S L14 OR L21

=> d l2

L2 HAS NO ANSWERS

L1 STR

A




Structure attributes must be viewed using STN Express query preparation.

L2 QUE ABB=ON PLU=ON L1

Aryl Fused Azapolycyclic Compounds

=> d 117
L17 HAS NO ANSWERS
L16 STR



Structure attributes must be viewed using STN Express query preparation.
L17 QUE ABB=ON PLU=ON L16

=> d ibib abs hitstr 1-23

Aryl Fused Azapolycyclic Compounds

L22 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004-80526 CAPLUS

DOCUMENT NUMBER: 140:144688

TITLE: Hapten-carrier conjugates comprising hormone, toxin, or drug for diagnosis and therapy

INVENTOR(S): Bachmann, Martin F.; Maurer, Patrik

PATENT ASSIGNEE(S): Cytos Biotechnology Ag, Switz.

SOURCE: PCT Int. Appl., 144 pp.

CODEN: PIXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009116	A2	20040129	WO 2003-EP7850	20030718
WO 2004009116	A3	20040318		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU
RW: GH, GM, KE, LS, MW, SD, SZ, SL, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG

US 2004059094 A1 20040325 US 2003-622064 20030718

PRIORITY APPLN. INFO.: US 2002-396575P 20020718

AB The present invention provides compns. comprising a conjugate of a hapten with a carrier in an ordered and repetitive array, and methods of making such compns. The conjugates and compns. of the invention may comprise a variety of haptens, including hormones, toxins and drugs, especially drugs of addiction such as nicotine. Compns. and conjugates of the invention are useful for inducing immune responses against haptens, which can use in a variety of therapeutic, prophylactic and diagnostic regimens. In certain embodiments, immune responses generated using the conjugates, compns. and methods of the present invention are useful to prevent or treat addiction to drugs of abuse and the resultant diseases associated with drug addiction.

IT 249296-44-4D, Varenicline, salts and optical isomers

375815-87-5, Varenicline tartrate


RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(hapten-carrier conjugates comprising a hormone, toxin, or drug and a core particle of bacteriophage protein for diagnosis and therapy)

RN 249296-44-4 CAPLUS

CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)

L22 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 375815-87-5 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-, (2R,3R)-2,3-dihydrobutanedicarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 249296-44-4
CMF C13 H13 N3



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003-622565 CAPLUS

DOCUMENT NUMBER: 139:179986

TITLE: Preparation of aryl-fused azapolycyclic compounds for reducing nicotine addiction

INVENTOR(S): Coe, Jotham Wadsworth; Brooks, Paige Roanne Palmer
PATENT ASSIGNEE(S): Pfizer Inc, USA
SOURCE: U.S., 39 pp., Cont.-in-part of Appl. No.

PCT/IB98/01813.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6605610	B1	20030812	US 2000-514002	20000225
WO 9935131	A1	19990715	WO 1998-IR1813	19981113

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, TZ, UG, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, UA, UG, US, UZ, VN, YU, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

US 6410550 B1 20020625 US 1999-402010 19990928

WO 2001062736 A1 20010830 WO 2001-IB153 20010208

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, UA, UG, US, UZ, VN, YU, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

RW: GH, GM, KE, LS, MW, SD, SI, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

BR 2001008610 A 20021119 BR 2001-8610 20010208

EP 1259489 A1 20021127 EP 2001-953630 20010208

R: AT, BE, CH, DE, DK, ES, PR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2003524002 T2 20030812 JP 2001-562518 20010208

EE 200200475 A 20031215 EE 2002-475 20010208

BG 106908 A 20030430 BG 2002-106908 20020705

ZA 2002006768 A 20030822 ZA 2002-6768 20020822

NO 2002004042 A 20021017 NO 2002-4042 20020823

US 2003130261 A1 20030710 US 2003-336508 20030103

US 2003130260 A1 20030710 US 2003-336533 20030103

PRIORITY APPLN. INFO.: US 1997-70245P P 19971231

WO 1998-IB1813 A2 19981113

US 1999-402010 A2 19990928


US 2000-514002 A 20000225

WO 2001-IB153 W 20010208

OTHER SOURCE(S): MARPAT 139:179986

GI

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB The invention discloses the preparation of aryl-fused azapolycyclic compds., such as I [R1 = H, alkyl, unconjugated alkenyl, benzyl, X(CO)R13, CH2CH20-alkyl; R2, R3 = H, alkenyl, alkynyl, OH, NO2, NH2, halo, CN, etc.]; or R2 and R3, together with the carbons to which they are attached, form a 4-7 membered monocyclic ring or a 10-14 membered bicyclic ring; R13 = H, alkyl; X = alkylene] and their pharmaceutically acceptable salts, as nicotine binding inhibitors (IC50 < 10 μM) in the treatment of neural and psychol. disorders. Thus, aryl-fused azapolycyclic compound I

(R1-R3 = H) was prepared via a multistep synthetic sequence starting from 2-fluorobromomethane.


IT 230615-08-4P 328055-86-3P 328055-99-BP

357424-19-3P 357424-20-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of aryl-fused azapolycyclic compds. as nicotine binding inhibitors)


RN 230615-08-4 CAPLUS

CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7,8-dinitro- (9CI) (CA INDEX NAME)



RN 328055-86-3 CAPLUS

CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro- (9CI) (CA INDEX NAME)




RN 328055-99-8 CAPLUS


CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 357424-19-2 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl- (9CI) (CA INDEX NAME)




RN 357424-20-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro- (9CI) (CA INDEX NAME)




IT 69718-72-5 230614-99-0 230615-00-6P
230615-01-7P 230615-02-8P 230615-03-9P
230615-04-OP 230615-05-1P 230615-06-2P
230615-07-3P 230615-09-5P 230615-10-8P
230615-11-9P 230615-12-0P 230615-13-1P
230615-14-2P 230615-15-3P 230615-16-4P
230615-17-5P 230615-18-6P 230615-19-7P
230615-20-OP 230615-21-1P 230615-22-2P
230615-23-3P 230615-24-4P 230615-25-5P
230615-26-6P 230615-27-7P 230615-28-8P
230615-29-9P 230615-30-2P 230615-31-3P
230615-32-4P 230615-33-5P 230615-34-6P
230615-35-7P 230615-36-8P 230615-37-9P
230615-38-0P 230615-39-1P 230615-40-4P
230615-41-5P 230615-42-6P 230615-43-7P
230615-44-8P 230615-45-9P 230615-46-0P
230615-75-5P 357425-82-2P 357425-83-3P
357425-84-4P 357425-86-6P 357425-87-7P
357425-88-8P 357425-89-9P 357425-90-2P
357425-91-3P 357425-92-4P 357425-93-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



● HCl
RN 230615-02-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl
RN 230615-03-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 6-fluoro-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl
RN 230615-04-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro-, monohydrochloride (9CI) (CA INDEX NAME)


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

(Uses)
(prepn. of aryl-fused azapolycyclic compds. as nicotine binding inhibitors)


RN 69718-72-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 230614-99-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)




● HCl
RN 230615-00-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl
RN 230615-01-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



● HCl
RN 230615-05-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-amine, 2,3,4,5-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl
RN 230615-06-2 CAPLUS
CN Acetamide, N-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl
RN 230615-07-3 CAPLUS
CN 5,9-Methano-5H-thiazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-09-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-10-8 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-11-9 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-15-3 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-butyl-1,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-16-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-17-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-12-0 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-13-1 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-14-2 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-propyl-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-18-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-19-7 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-20-0 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-1,5,6,7,8,9-hexahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-21-1 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-22-2 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-, 1,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-23-3 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-27-7 CAPLUS
CN Benzamide, 2-fluoro-N-(2,3,4,5-tetrahydro-8-hydroxy-1,5-methano-1H-3-benzazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-28-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-29-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-24-4 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-25-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-26-6 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-30-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(5-methyl-1,2,4-oxadiazol-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-31-3 CAPLUS
CN Ethanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-32-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-33-5 CAPLUS
CN 5,9-Methano-5H-3-oxazolo[4,5-h][3]benzazepine,
6,7,8,9-tetrahydro-3-methyl-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-34-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine,
2,3,4,5-tetrahydro-7-(1-methyl-1H-pyrazol-5-
yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-35-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine,
2,3,4,5-tetrahydro-7-(1-methyl-1H-pyrazol-3-

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
y1)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-36-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro-,
hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-37-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N,N-
dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-38-0 CAPLUS
CN Pyrrolidine, 1-[(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-
yl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-39-1 CAPLUS
CN 1,5-Methanopyrrolo[2,3-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-42-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-6-ol, 2,3,4,5-tetrahydro-, hydrochloride
(9CI) (CA INDEX NAME)



● HCl


RN 230615-40-4 CAPLUS
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one, 3,5,6,7,8,9-hexahydro-,
monohydrochloride (9CI) (CA INDEX NAME)

RN 230615-43-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-difluoro-2,3,4,5-tetrahydro-,
hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-41-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-phenyl-, hydrochloride
(9CI) (CA INDEX NAME)




● HCl

RN 230615-44-8 CAPLUS
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepine, 2-ethyl-6,7,8,9-tetrahydro-,
monohydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapoly(cyclic Compounds)

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-45-9 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-46-0 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-75-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357425-82-2 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 357425-83-3 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 357425-84-4 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 357425-86-6 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7-ethyl-7,8,9,10-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 357425-87-7 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-4-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 357425-88-8 CAPLUS
CN 6,10-Methano-2H-pyrido[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-, dihydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● 2 HCl

RN 357425-89-9 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-7,8,9,10-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 357425-90-2 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 357425-91-3 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-5-fluoro-7,8,9,10-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



● HCl

RN 357425-92-4 CAPLUS
CN 6,10-Methano-2H-pyrazino[2,3-h][3]benzazepin-2-one,
1,6,7,8,9,10-hexahydro-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 357425-93-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 69718-72-5
CMF C11 H13 N



CM 2

CRN 104-15-4
CMF C7 H8 O3 S

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




IT 230615-52-8 357426-15-4 357426-16-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of aryl-fused azapolycyclic compds. as nicotine binding inhibitors)
RN 230615-52-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-, hydrochloride (9CI)
(CA INDEX NAME)




● HCl

RN 357426-15-4 CAPLUS
CN Ethanethioamide,
2,2,2-trifluoro-N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoro-1-thioxoethyl)-1,5-methano-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 357426-16-5 CAPLUS
CN 5,9-Methano-5H-thiazolo[4,5-h][3]benzazepine,
6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT 230615-48-2P 230615-50-6P 230615-51-7P
230615-53-9P 230615-56-2P 230615-57-3P
230615-59-5P 230615-60-8P 230615-61-9P
230615-62-0P 230615-63-1P 230615-64-2P
230615-65-3P 230615-66-4P 230615-67-5P
230615-68-6P 230615-69-7P 230615-70-0P
230615-71-1P 230615-72-2P 230615-73-3P
230615-74-4P 230615-77-7P 230615-78-8P
230615-79-9P 230615-80-2P 230615-81-3P
230615-82-4P 230615-83-5P 230615-84-6P
230615-85-7P 230615-86-8P 230615-88-0P
230615-89-1P 230615-92-6P 230615-93-7P
357425-94-6P 357425-95-7P 357425-96-8P
357425-97-9P 357425-98-0P 357425-99-1P
357426-00-7P 357426-01-8P 357426-02-9P
357426-04-1P 357426-05-2P 357426-06-3P
357426-07-4P 357426-08-5P 357426-09-6P
357426-10-9P 357426-13-2P 357426-17-6P
357426-18-7P 357426-19-8P 357426-20-1P
357426-21-2P 357426-22-3P 357426-23-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aryl-fused azapolycyclic compds. as nicotine binding inhibitors)
RN 230615-48-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 230615-50-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine,
7-fluoro-2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 230615-51-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-53-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-56-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-amine, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-57-3 CAPLUS
CN Acetamide, N-[2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 230615-59-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7,8-dinitro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-60-8 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7,8-dinitro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-61-9 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7,8-diamino-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-62-0 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-63-1 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-2-methyl-1-propyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-68-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-2-methyl-1-(2-methylpropyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-69-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7,8-diamine, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-70-0 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-71-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-ol, 2,3,4,5-tetrahydro-8-nitro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-64-2 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-65-3 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-(butylamino)-1,2,4,5-tetrahydro-8-nitro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-66-4 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-amino-8-(butylamino)-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-67-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 1-butyl-5,6,8,9-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-72-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 8-amino-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-73-3 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-74-4 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-77-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-iodo-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-78-8 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid,
2,3,4,5-tetrahydro-7-iodo-
, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-79-9 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid,
7-cyano-1,2,4,5-tetrahydro-
, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-80-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-acetyl-2,3,4,5-tetrahydro-3-
(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-81-3 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-acetyl-1,2,4,5-
tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-86-8 CAPLUS
CN 5,9-Methano-5H-1,3-benzodiazepolo[4,5-h][3]benzazepine,
6,7,8,9-tetrahydro-3-methyl-
7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-88-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro-3-
(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-89-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-sulfonyl chloride, 2,3,4,5-tetrahydro-3-
(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-92-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-iodo-3-(phenylmethyl)-
(9CI) (CA INDEX NAME)


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-82-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol,
2,3,4,5-tetrahydro-3-(trifluoroacetyl)-
acetate (ester) (9CI) (CA INDEX NAME)



RN 230615-83-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)-
(9CI) (CA INDEX NAME)




RN 230615-84-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 8-acetyl-2,3,4,5-tetrahydro-3-
(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-85-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-8-[1-
(hydroxymino)ethyl]-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-93-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine,
2,3,4,5-tetrahydro-6-phenyl-3-(phenylmethyl)-
(9CI) (CA INDEX NAME)



RN 357425-94-6 CAPLUS
CN Ethenethioamide, N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoro-1-thioxoethyl)-
1,5-methano-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 357425-95-7 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine,
2-chloro-6,7,8,9-tetrahydro-7-
(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357425-96-8 CAPLUS
CN Boronic acid, [2,3,4,5-tetrahydro-3-(phenylmethyl)-1,5-methano-1H-3-
benzazepin-7-yl]- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357425-97-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-3-(phenylimethyl)- (9CI) (CA INDEX NAME)



RN 357425-98-0 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357425-99-1 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methyl-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357426-00-7 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-3-methyl-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357426-06-3 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 357426-07-4 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine-8-carboxylic acid, 2-chloro-6,7,9,10-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 357426-08-5 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine-8-carboxylic acid, 6,7,9,10-tetrahydro-2-methoxy-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 357426-09-6 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine-8-carboxylic acid, 2-chloro-5-fluoro-6,7,9,10-tetrahydro-, methyl ester (9CI) (CA INDEX NAME)


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357426-01-8 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 3-ethyl-7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 357426-02-9 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-4-methyl-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357426-04-1 CAPLUS
CN Propanamide, 3,3-dimethoxy-N-[2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 357426-05-2 CAPLUS
CN 6,10-Methano-2H-pyrido[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357426-10-9 CAPLUS
CN 6,10-Methano-2H-pyrazino[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 357426-13-2 CAPLUS
CN 1,5-Methano-2H-benzazepin-2-one, 1,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 357426-17-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 1-(2-dimethylpropyl)-5,6,8,9-tetrahydro-, 1,1-dimethylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



RN 357426-18-7 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 1-(2-dimethylpropyl)-5,6,8,9-tetrahydro-2-methyl-, 1,1-dimethylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 357426-19-8 CAPLUS
CN 6,10-Methano-8H-pyrazino[2,3-h][3]benzazepine-8-carboxylic acid, 6,7,9,10-tetrahydro-2,3-dimethyl-, 1,1-dimethylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 357426-20-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carboximidamide, 2,3,4,5-tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 357426-21-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-[3-(dimethylamino)-1-oxo-2-propenyl]-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:434575 CAPLUS
DOCUMENT NUMBER: 139:966
TITLE: Aryl fused azapolycyclic compounds for the treatment of nicotine addiction/withdrawal and CNS disorders
INVENTOR(S): Obach, Ronald Scott; Hagen, Anne Elizabeth
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 20 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045967	A1	20030605	WO 2002-IB4820	20021118
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BP, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
US 2003166582	A1	20030904	US 2002-306500	20021127
PRIORITY APPN. INFO.: OTHER SOURCE(S): G1			US 2001-334502P	P 20011130
MARPAT 139:966				




AB The invention discloses aryl fused azapolycyclic compds. I [R1 = H, COOR (R4 = Q1, Q2); R2, R3 = bicyclic ring system-forming moieties, etc.], and their pharmaceutically acceptable salts; intermediates for the synthesis of such compds.; and methods of using such compds. in the treatment of nicotine addiction/withdrawal and CNS disorders. The


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 357426-22-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N,N-dimethyl-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 357426-23-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(1-pyrrolidinylsulfonyl)-3-(trifluoroacetyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
tetrahydromethanobenzazepine derivs. of the invention bind to neuronal nicotinic acetylcholine receptor sites and are useful in modulating cholinergic function.


IT 249296-44-4 357426-21-6 535920-98-0
RL: BSB (Biological study, unclassified); PKT (Pharmacokinetics); BIOL (Biological study)
(aryl) fused azapolycyclic compds. for treatment of nicotine addiction/withdrawal and other disorders)

RN 249296-44-4 CAPLUS

CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-21-6 CAPLUS
CN 6,10-Methano-2H-pyrazino[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro- (9CI) (CA INDEX NAME)



RN 535920-98-0 CAPLUS
CN β-D-Glucopyranuronic acid, 1-(6,7,9,10-tetrahydro-6,10-methano-8H-pyrazino[2,3-h][3]benzazepin-8-carboxylate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 69718-72-50, derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aryl) fused azapolycyclic compds. for treatment of nicotine addiction/withdrawal and other disorders)

RN 69718-72-5 CAPLUS

CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L22 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:434404 CAPLUS
DOCUMENT NUMBER: 139:12305
TITLE: Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene.
INVENTOR(S): Am Ende, Mary Tanya; Roy, Michael Christopher; Smith, Scott Wendell; Waterman, Kenneth Craig; Moses, Sara Kristen; Quan, Ernest Shing
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045437	A1	20030605	WO 2002-IB4612	20021104
WO 2003045437	C1	20030814		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TO				
US 2003180360	A1	20030925	US 2002-300608	20021120
PRIORITY APPLN. INFO.: US 2001-334652P P 20011130 GI				



AB The present invention is directed to controlled-release (CR) oral pharmaceutical dosage forms of I and pharmaceutically acceptable salts thereof, and methods of using them to reduce nicotine addiction or aiding in the cessation or lessening of tobacco use while reducing nausea as an adverse effect. The present invention also relates to an immediate-release (IR) low dosage composition having a stable formulation with uniform drug distribution and potency. Controlled-release tablets of I L-tartarate were prepared
IT 249296-44-4 375815-87-5 536696-70-5
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9]

L22 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 249296-44-4 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)



RN 375815-87-5 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 249296-44-4
CMP C13 H13 N3



CM 2

CRN 87-69-4
CMP C4 H6 O6

Absolute stereochemistry.




RN 536696-70-5 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 249296-44-4
CMP C13 H13 N3

L22 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 77-92-9
CMP C6 H8 O7



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

Aryl Fused Azapolycyclic Compounds

L22 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:434372 CAPLUS
 DOCUMENT NUMBER: 139:12300
 TITLE: Preparation of triazatetracycloentaene succinate for pharmaceutical compositions
 INVENTOR(S): Quallich, George Joseph; Wint, Lewin Theophilus
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 21 pp.
 CODEN: PIIXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045394	A1	20030605	WO 2002-IB4380	20021021
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TU, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
US 2003149044	A1	20030807	US 2002-305845	20021127

PRIORITY APPLN. INFO.: US 2001-334245P P 20011129
 AB The present invention is directed to the 5,8,14-triazatetracyclo[10.3.1.0_{2,11}.0_{4,9}]pentadeca-2(11),3,5,7,9-pentaene succinate salt (I) and pharmaceutical compns. thereof. The invention is also directed to a process for preparation of the salts. Thus, I was prepared by

the reaction of the free base with succinic acid in 2-PrOH. The compound was characterized by x-ray diffraction studies.

IT 535959-68-39
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of triazatetracycloentaene succinate for pharmaceutical compns.)

RN 535959-68-3 CAPLUS
 CN Butanedioic acid, compd. with 7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine (1:1) (9CI) (CA INDEX NAME)

CM 1
 CRN 249296-44-4
 CMF C13 H13 N3

L22 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




CM 2

CRN 110-15-6
 CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

IT 535959-69-49
 RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of triazatetracycloentaene succinate for pharmaceutical compns.)
 RN 535959-69-4 CAPLUS
 CN Butanedioic acid, compd. with 7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine (1:1) (9CI) (CA INDEX NAME)

CM 1
 CRN 249296-44-4
 CMF C13 H13 N3



CM 2

CRN 110-15-6
 CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

IT 249296-44-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of triazatetracycloentaene succinate for pharmaceutical compns.)
 RN 249296-44-4 CAPLUS

L22 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

ACCESSION NUMBER: 2003:356250 CAPLUS
 DOCUMENT NUMBER: 138:348736
 TITLE: Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome
 INVENTOR(S): Saltarelli, Mario David
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 37 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200307329	A1	20030508	WO 2002-IB4379	20021021
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TU, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EB, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
US 2003134844	A1	20030717	US 2002-224055	20020820

PRIORITY APPLN. INFO.: US 2001-334810P P 20011031
 US 2001-335458P P 20011126

OTHER SOURCE(S): MARPAT 138:348736
 AB The invention discloses the use of nicotinic acetylcholine receptor agonists for the treatment of restless leg syndrome (RLS). The invention further discloses the use of a nicotinic acetylcholine receptor agonist in the manufacture of a medicament for the treatment of RLS. The invention also discloses a pharmaceutical composition for the treatment of RLS containing a

nicotinic acetylcholine receptor agonist.

IT 69718-72-5 23085-73-5 249296-44-4
 287973-26-6 328055-80-7 328055-84-1
 328055-85-2 328055-86-3 328055-87-4
 328055-88-3 328055-89-6 328055-90-9
 328055-92-1 328055-94-3 328055-95-4
 328055-96-5 328055-97-6 328055-98-7
 328055-99-5 357424-11-2 357424-03-4
 357424-04-5 357424-11-4 357424-12-5
 357424-13-6 357424-14-7 357424-15-8
 357424-16-3 357424-18-1 357424-19-2
 357424-20-5 357424-21-6 357424-22-7
 357424-23-5 357424-24-9 357424-25-0
 357424-26-3 357424-32-9 357424-34-1
 357424-27-4 357424-37-5 357424-39-6
 357424-42-0 357424-43-2 357424-45-4
 357424-47-6 357424-49-8 357424-51-2
 357426-16-5 519165-22-1 519165-23-2
 519165-24-3 519165-25-4 519165-26-5

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

519165-27-6 519165-28-7 519165-29-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(nicotinic agonists for treatment of restless legs syndrome)


RN 69718-72-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 230615-75-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 249296-44-4 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)




RN 287973-26-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-difluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-80-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)

HN


L22 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-84-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)



RN 328055-85-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 328055-86-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro- (9CI) (CA INDEX NAME)




RN 328055-87-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl- (9CI) (CA INDEX NAME)


L22 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-88-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 328055-89-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl- (9CI) (CA INDEX NAME)



RN 328055-90-9 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl- (9CI) (CA INDEX NAME)




RN 328055-92-1 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl- (9CI) (CA INDEX NAME)

HN


L22 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-94-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-95-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-96-5 CAPLUS
CN Ethanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 328055-97-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-98-7 CAPLUS
CN 5,9-Methano-5H-isoxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl-

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 (9CI) (CA INDEX NAME)




RN 328055-99-8 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 357424-02-3 CAPLUS
 CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 357424-03-4 CAPLUS
 CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 357424-04-5 CAPLUS
 CN Benzamide, 2-fluoro-N-(2,3,4,5-tetrahydro-8-hydroxy-1,5-methano-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)

o


L22 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-15-8 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 357424-16-9 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-phenyl- (9CI) (CA INDEX NAME)




RN 357424-18-1 CAPLUS
 CN 5,9-Methanimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)- (9CI) (CA INDEX NAME)




RN 357424-19-2 CAPLUS
 CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl- (9CI) (CA INDEX NAME)


L22 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-11-4 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-propyl- (9CI) (CA INDEX NAME)



RN 357424-12-5 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 357424-13-6 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-propyl- (9CI) (CA INDEX NAME)




RN 357424-14-7 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-butyl-1,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)


L22 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-20-5 CAPLUS
 CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro- (9CI) (CA INDEX NAME)



RN 357424-21-6 CAPLUS
 CN 6,10-Methano-2H-pyrazino[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro- (9CI) (CA INDEX NAME)



RN 357424-22-7 CAPLUS
 CN 1,5-Methano-1H-3-benzazepin-7-amine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-23-8 CAPLUS
 CN Acetamide, N-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 357424-24-9 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(5-methyl-1,2,4-

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
oxadiazol-3-yl)- (9CI) (CA INDEX NAME)



RN 357424-25-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 357424-26-1 CAPLUS
CN Pyrrolidine, 1-[(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 357424-32-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 357424-34-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 6-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)


L22 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-36-3 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)



RN 357424-37-4 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 357424-39-6 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)




RN 357424-41-0 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 3-ethyl-7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)


L22 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-43-2 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-4-methyl- (9CI) (CA INDEX NAME)




RN 357424-45-4 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro- (9CI) (CA INDEX NAME)



RN 357424-47-6 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-49-8 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methoxy- (9CI) (CA INDEX NAME)




L22 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 357424-51-2 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-5-fluoro-7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)




RN 357426-16-5 CAPLUS
CN 5,9-Methano-5H-thiazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 519165-22-1 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 519165-23-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(1-methyl-1H-pyrazol-5-yl)- (9CI) (CA INDEX NAME)



RN 519165-24-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(1-methyl-1H-pyrazol-3-

Aryl Fused Azapolycyclic Compounds

L22 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
y1 - (9CI) (CA INDEX NAME)




RN 519165-25-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-phenyl- (9CI) (CA INDEX NAME)



RN 519165-26-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-6-ol, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 519165-27-6 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h] [3]benzazepine, 2-ethyl-6,7,8,9-tetrahydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 519165-28-7 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h] [3]benzazepine, 6,7,8,9-tetrahydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)

L22 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 519165-29-8 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h] [3]benzazepine, 6,7,8,9-tetrahydro-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

~~X~~ ANSWER 7 OF 23 CAPLUS, COPYRIGHT 2004 ACS on STN
DECESSION NUMBER: 2003:23533 CAPLUS
DOCUMENT NUMBER: 138:83396
TITLE: Pharmaceutical composition and method of modulating cholinergic function in a mammal
INVENTOR(S): Coe, Jotham W.; Sanda, Steven B.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 23 PP.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003008892	A1	20030109	US 2002-105605	20020325
WO 2003005998	A2	20030123	WO 2002-IB1767	20020521
WO 2003005998	A3	20030530		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, C2, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NC, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, Tj, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	ABN	NZ 2002-529607 A 20031219 NZ 2002-529607 20020521 EP 1404320 A2 20040407 EP 2002-727942 20020521 R: AT, BE, CH, DE, DK, ES, FR, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR PRIORITY APPLN. INFO.: US 2001-303957 P 20010709 WO 2002-IB1767 W 20020521		

AB A composition for modulating cholinergic function in a mammal comprises a nicotinic receptor partial agonist (NRPA) in combination with an anti-emetic/anti-nausea agent and a pharmaceutically acceptable carrier. The NRPA compound and the anti-emetic/anti-nausea agent are present in amounts that render the composition effective modulating cholinergic function or in the treatment of various disorders or conditions selected from inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alc., benzodiazepines, barbiturates, opioids or cocaine), headache, migraine, stroke, traumatic brain injury (TBI), obsessive compulsive disorder (OCD), psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome. The method of using these compns. is also disclosed.

L22 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
deficit hyperactivity disorder (ADHD) and Tourette's Syndrome. The method

of using these compns. is also disclosed.


IT 69718-72-5 245296-44-4 287973-26-6
287973-27-7 328055-77-2 328055-78-3
328055-79-4 328055-80-7 328055-81-0
328055-83-0 328055-84-1 328055-85-2
328055-86-3 328055-87-4 328055-88-5
328055-89-6 328055-90-9 328055-92-1
328055-94-3 328055-95-4 328055-96-5
328055-97-6 328055-99-8 328055-66-2
357424-19-2 367511-27-1 367511-30-6
367511-38-4

RU THU (therapeutic use); BIOL (Biological study); USES (Uses) (compone. containing nicotinic receptor partial agonist in combination with antiemetic for modulating cholinergic function)


RN 69718-72-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 249296-44-4 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h] [3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)




RN 287973-26-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-difluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 287973-27-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-ethynyl-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-77-2 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 328055-78-3 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 328055-79-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 328055-80-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)


L22 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-86-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro- (9CI) (CA INDEX NAME)



RN 328055-87-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl- (9CI) (CA INDEX NAME)




RN 328055-88-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 328055-89-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl- (9CI) (CA INDEX NAME)


L22 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-81-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-ethynyl-8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-83-0 CAPLUS
CN 1,5-Methano-2H-thiazolo[4,5-h][3]benzazepine, 3,5,6,7,8,9-hexahydro-2-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 328055-84-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)




RN 328055-85-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-90-9 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl- (9CI) (CA INDEX NAME)




RN 328055-92-1 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl- (9CI) (CA INDEX NAME)



RN 328055-94-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-95-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



Aryl Fused Azapolycyclic Compounds


L22 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 328055-96-5 CAPLUS
 CN Ethanone, 1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (9CI)
 (CA INDEX NAME)




RN 328055-97-6 CAPLUS
 CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-99-8 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328056-66-2 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-19-2 CAPLUS
 CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl- (9CI) (CA INDEX NAME)


L22 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 367511-27-1 CAPLUS
 CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-3(5H)-one, 6,7,8,9-tetrahydro- (9CI) (CA INDEX NAME)



RN 367511-30-6 CAPLUS
 CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-3(5H)-one, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 367511-38-4 CAPLUS
 CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(5H)-one, 6,7,8,9-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)



L22 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002-888737 CAPLUS
 DOCUMENT NUMBER: 137-375226
 TITLE: The citrate salt of 5, 8, 14-triazatetracyclo[10.3.1.0_{2,11}.0_{4,9}]hexadeca-2,(11),3,5,7,9-pentane and pharmaceutical

compositions thereof

INVENTOR(S): Johnson, Philip James; Rose, Peter Robert; Wint, Lewin

PATENT ASSIGNEE(S): Theophilus; Williams, Glenn Robert

Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092597	A1	20021121	WO 2002-IB1450	20020426
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
EP 20030366	A1	20040225	EP 2002-724553	20020426
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300557	A	20040415	EE 2003-557	20020426
US 2003149091	A1	20030807	US 2002-139449	20020506
NO 2003005035	A	20031113	NO 2003-5035	20031113
PRIORITY APPLN. INFO.:			US 2001-290863P	P 20010514
			WO 2002-IB1450	W 20020426

AB The present invention is directed to the citrate salt of 5, 8, 14-triazatetracyclo[10.3.1.0_{2,11}.0_{4,9}]hexadeca-2,(11),3,5,7,9-pentane and pharmaceutical compns. thereof. The present invention is also directed

to the various forms for the citrate salt, particularly its hydrate and its anhydrous/nearly anhydrous polymorph. The invention is also directed to processes for preparation of these citrate salt forms.

IT 475478-66-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIO (Biological study); PREP (Preparation); USES (Uses)

(citrate salt of azatetracyclohexadecapentaene and pharmaceutical compns. thereof)


RN 475478-66-1 CAPLUS

CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-hydroxy-1,2,3-propanetricarboxylate (1:1), monohydrate (9CI) (CA INDEX NAME)

CM 1


L22 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

CRN 249296-44-4
 CMF C13 H13 N3




CM 2

CRN 77-92-9
 CMF C6 H8 O7



IT 249296-44-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (citrate salt of azatetracyclohexadecapentaene and pharmaceutical compns. thereof)

RN 249296-44-4 CAPLUS
 CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:888559 CAPLUS
 DOCUMENT NUMBER: 137:375274
 TITLE: Preparation of pharmaceutical compositions of tartrate salts of 5,8,14-triazatetracyclo[10.3.1.0_{2,11}.0_{4,9}]hexadeca-2(11),3,5,7,9-pentaene
 INVENTOR(S): Bogle, David Everett; Rose, Peter Robert; Williams, Glenn Robert
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 63 pp
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092089	A1	20021121	WO 2002-IB1437	20020426
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1392307	A1	20040303	EP 2002-722625	20020426
R: AT, BE, CH, DE, DK, ES, FR, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002009605	A	20040323	BR 2002-9605	20020426
EE 200300556	A	20040415	EE 2003-556	20020426
US 2003166701	A1	20030904	US 2002-139730	20020506
NO 2003005036	A	20031113	NO 2003-5036	20031113


PRIORITY APPLN. INFO.: US 2001-290861P P 20010514
 WO 2002-IB1437 W 20020426
 AB The present invention is directed to the tartrate salts of 5,8,14-triazatetracyclo[10.3.1.0_{2,11}.0_{4,9}]hexadeca-2(11),3,5,7,9-pentaene (I), and their pharmaceutical compns. The present invention in particular is directed to the L-tartrate salt, and further to the various polymorphs of the L-tartrate salt, including 2 distinct anhydrous polymorphs (referred to herein as Forms A and B) and a hydrate polymorph (referred to as Form C). In addition, the present invention is also directed to the D-tartrate salt of I and the various polymorphs as well as the DL-tartrate salt and its polymorphs, and the mesotartrate salt and its polymorphs. Thus, polymorphs of I L-tartrate salt were prepared by the reaction of the drug base with L-tartaric acid in MeOH. The forms were characterized by x-ray diffraction, DSC and spectrometry.
 IT 375815-87-5P, CP 526555-18 475470-33-BP
 475470-34-9P

L22 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIO (Biological study); PREP (Preparation); USES (Uses)
 (pharmaceutical compns. containing polymorphs of tartrate salts of triazatetracyclohexadecapentaene)
 RN 375815-87-5 CAPLUS
 CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)
 CM 1
 CRN 249296-44-4
 CMF C13 H13 N3




CM 2
 CRN 87-69-4
 CMF C4 H6 O6

Absolute stereochemistry.



RN 475470-33-8 CAPLUS
 CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1), monohydrate (9CI) (CA INDEX NAME)
 CM 1
 CRN 249296-44-4
 CMF C13 H13 N3




L22 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


L22 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

CM 2
 CRN 87-69-4
 CMF C4 H6 O6


Absolute stereochemistry.



RN 475470-34-9 CAPLUS
 CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-, rel-(2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT



CM 2

CRN 133-37-9
 CMF C4 H6 O6

Relative stereochemistry.



IT 249296-44-4, CP 526555
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (pharmaceutical compns. containing polymorphs of tartrate salts of triazatetracyclohexadecapentaene)

RN 249296-44-4 CAPLUS
 CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds



L22 ANSWER 10 OF 23 CAPIUS COPYRIGHT 2004 ACS on STN
 ACESSION NUMBER: 2002832750 CAPIUS
 DOCUMENT NUMBER: 137:337794
 TITLE: Process for the preparation of 1,3-substituted
 indenes
 and aryl-fused azapolycyclic compounds
 INVENTOR(S): Singer, Robert Alan; McKinley, Jason Daniel
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 96 pp.
 CODEN: PIXD2
 DOCUMENT TYPE: patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

no Gdp

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085843	A2	20021031	WO 2002-IB660	20020304
WO 2002085843	A3	20030605		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BO, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
EP 1383733	A2	20040128	EP 2002-701498	20020304
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003060624	A1	20030327	US 2002-124135	20020417
PRIORITY APPLN. INFO.: US 2001-285131P P 20010420				
OTHER SOURCE(S): MARPAT 137:337794			WO 2002-IB660	W 20020304

GI


L22 ANSWER 10 OF 23 CAPIUS COPYRIGHT 2004 ACS on STN (Continued)



AB: The 1,3-substituted indenes I-III [R₁ = CN, alkoxy carbonyl, acyl, aryl, NO₂, CF₃, sulfonyl; R₂, R₃ = H, F, Cl, alkylthio, alkylsulfinyl, alkylsulfonyl, (un)substituted NH₂, CO₂H, SO₂NH₂, alkoxy etc.; R₄ = H, ammonium, alkali metal; R₅ = alkyl, trialkylsilyl, SiPh₃] were prepared as intermediates for the benzoazocyclooctanones IV which modulate cholinergic function. Thus, 2-BzC₆H₄CN:CHCH₂CO₂M₊ was treated with MeOH:CHCO₂M₋ to give 2-BzC₆H₄CN:CHCH₂CO₂M₋ which was cyclized to 3-(hydroxymethoxy(methylene)-3H-indene-1-carbonitrile sodium salt. Reductive cyclization of the latter compound gave 2,3,4,5-tetrahydro-1,5-methano-1H-benzazepin-2-one.


IT: 230615-04-OP 230615-08-4P 230615-51-7P
 230615-52-8P 230615-53-9P 230615-54-0P
 230615-55-1P 230615-56-2P 230615-57-3P
 230615-59-5P 230615-60-8P 230615-61-9P
 230615-62-0P 230615-63-1P 230615-64-2P
 230615-65-3P 230615-66-4P 230615-67-5P
 230615-68-6P 230615-69-7P 230615-70-0P
 230615-71-1P 230615-72-2P 230615-73-3P
 230615-74-4P 230615-75-5P 230615-76-6P
 230615-77-7P 230615-78-8P 230615-79-9P
 230615-80-2P 230615-81-3P 230615-82-4P
 230615-83-5P 230615-84-6P 230615-85-7P
 230615-86-8P 230615-88-0P 230615-89-1P
 245296-44-4P 248055-86-3P 248055-99-8P
 357424-20-5P 357424-25-0P 357424-47-6P
 357425-94-6P 357425-98-0P 357425-99-1P
 357426-00-7P 357426-01-8P 357426-02-9P
 357426-04-1P 357426-05-2P 357426-06-3P
 357426-07-4P 357426-08-5P 357426-10-9P
 357426-21-2P 474024-46-9P 474024-47-0P
 474024-48-1P 474024-59-4P

L22 ANSWER 10 OF 23 CAPIUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl


RN: 230615-53-9 CAPIUS
 CN: 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro-3-(trifluoroacetyl) (CA INDEX NAME)



RN: 230615-54-0 CAPIUS
 CN: 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-nitro-, 1,1-dimethyl ethyl ester (9CI) (CA INDEX NAME)




RN: 230615-55-1 CAPIUS
 CN: 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-amino-1,2,4,5-tetrahydro-, 1,1-dimethyl ethyl ester (9CI) (CA INDEX NAME)




RN: 230615-56-2 CAPIUS
 CN: 1,5-Methano-1H-3-benzazepin-7-amine, 2,3,4,5-tetrahydro-3-(trifluoroacetyl) (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-57-3 CAPLUS
CN Acetamide, N-[2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 230615-59-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7,8-dinitro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-60-8 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7,8-dinitro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-61-9 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7,8-diamino-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-62-0 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-63-1 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-2-methyl-1-propyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-64-2 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-65-3 CAPLUS


L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-(butylamino)-1,2,4,5-tetrahydro-8-nitro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-66-4 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-amino-8-(butylamino)-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-67-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 1-butyl-5,6,8,9-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-68-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-2-methyl-1-(2-methylpropyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-69-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7,8-diamine, 2,3,4,5-tetrahydro-3-


L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-70-0 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-71-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-8-nitro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-72-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 8-amino-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-73-3 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-74-4 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-75-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-76-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-77-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-iodo-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-82-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)-, acetate (ester) (9CI) (CA INDEX NAME)



RN 230615-83-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-84-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 8-acetyl-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-85-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-8-[1-(hydroxyimino)ethyl]-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-78-8 CAPLUS
CN 1,5-Methano-3H-oxazolo[4,5-h][3]benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-iodo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-79-9 CAPLUS
CN 1,5-Methano-3H-oxazolo[4,5-h][3]benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-cyano-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-80-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-acetyl-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-81-3 CAPLUS
CN 1,5-Methano-3H-oxazolo[4,5-h][3]benzazepine-3-carboxylic acid, 7-acetyl-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-86-8 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-88-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-89-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-sulfonyl chloride, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 249296-44-4 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-86-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro- (9CI) (CA INDEX NAME)



RN 328055-99-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-20-5 CAPLUS
CN 5,9-Methano-6H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-25-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)


L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-47-6 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)



RN 357425-94-6 CAPLUS
CN Ethanethioamide, N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoro-1-thioxoethyl)-1,5-methano-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 357425-98-0 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357425-99-1 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methyl-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357426-00-7 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-3-methyl-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 357426-01-8 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 3-ethyl-7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357426-02-9 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-4-methyl-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357426-04-1 CAPLUS
CN Propanamide, 3,3-dimethoxy-N-(2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)


L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357426-05-2 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 357426-06-3 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357426-07-4 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine-8-carboxylic acid, 2-chloro-7,8,9,10-tetrahydro-, 1,1-dimethyl ethyl ester (9CI) (CA INDEX NAME)




RN 357426-08-5 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine-8-carboxylic acid, 6,7,9,10-tetrahydro-2-methoxy-, 1,1-dimethyl ethyl ester (9CI) (CA INDEX NAME)

Aryl Fused Azapoly(cyclic Compounds)


L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357426-10-9 CAPLUS
CN 6,10-Methano-2H-pyrazino[2,3-h][3]benzazepin-2-one,
1,6,7,8,9,10-hexahydro-
8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 357426-21-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-[3-(dimethylamino)-1-oxo-2-propenyl]-
2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 474024-46-9 CAPLUS
CN 1,5-Methano-2H-3-benzazepine-3-carboxylic acid,
7-amino-1,2,4,5-tetrahydro-
8-[(2-methylpropyl)amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX
NAME)




RN 474024-47-0 CAPLUS


1.22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 1,5-Methano-1H-3-benzazepine,
2,3,4,5-tetrahydro-7-(1-methyl-1H-pyrazol-5-
yl)-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 474024-48-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine,
2,3,4,5-tetrahydro-7-(1-methyl-1H-pyrazol-3-
yl)-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 474024-59-4 CAPLUS
CN 6,10-Methano-2H-pyrazino[2,3-h][3]benzazepine-8-carboxylic acid,
6,7,9,10-tetrahydro-2,3-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA
INDEX NAME)




IT 230615-05-1P 230615-06-2P 230615-07-3P
230615-09-5P 230615-10-8P 230615-11-9P
230615-12-0P 230615-13-1P 230615-14-2P
230615-15-3P 230615-16-4P 230615-17-5P
230615-18-6P 230615-19-7P 230615-20-0P
230615-21-1P 230615-22-2P 230615-23-3P
230615-24-4P 230615-25-5P 230615-26-6P
230615-27-7P 230615-28-8P 230615-29-9P
230615-30-2P 230615-31-3P 230615-32-4P
230615-33-5P 230615-34-6P 230615-35-7P
230615-36-8P 230615-37-9P 230615-38-0P

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 5,9-Methanimidazo[4,5-h][3]benzazepine,
1,5,6,7,8,9-hexahydro-2-methyl-1-
propyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-10-8 CAPLUS
CN 5,9-Methanimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-11-9 CAPLUS
CN 5,9-Methanimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-12-0 CAPLUS
CN 5,9-Methanimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-,
monohydrochloride (9CI) (CA INDEX NAME)

RN 230615-06-2 CAPLUS
CN Acetamide, N-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)-,
monohydrochloride (9CI) (CA INDEX NAME)




RN 230615-07-3 CAPLUS
CN 5,9-Methano-5H-thiazolo[4,5-h][3]benzazepine,
6,7,8,9-tetrahydro-2-methyl-,
monohydrochloride (9CI) (CA INDEX NAME)



RN 230615-09-5 CAPLUS


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-13-1 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-14-2 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-15-3 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-butyl-1,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-16-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-17-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-18-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-19-7 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-20-0 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-1,5,6,7,8,9-hexahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-21-1 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-22-2 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-1,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-23-3 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-24-4 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-25-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-26-6 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine,
6,7,8,9-tetrahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-27-7 CAPLUS
CN Benzamide, 2-fluoro-N-(2,3,4,5-tetrahydro-8-hydroxy-1,5-methano-1H-3-benzazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-31-3 CAPLUS
CN Ethenone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-32-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-33-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine,
6,7,8,9-tetrahydro-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-28-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-29-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-30-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(5-methyl-1,2,4-oxadiazol-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-34-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine,
2,3,4,5-tetrahydro-7-(1-methyl-1H-pyrazol-5-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-35-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine,
2,3,4,5-tetrahydro-7-(1-methyl-1H-pyrazol-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-36-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-37-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-38-0 CAPLUS
CN Pyrrolidine, 1-((2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)sulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-39-1 CAPLUS
CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-40-4 CAPLUS
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one, 3,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 357425-82-2 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 357425-83-3 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● 2 HCl

RN 357425-86-6 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 3-ethyl-, 7,8,9,10-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 357425-87-7 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-4-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 357425-88-8 CAPLUS
CN 6,10-Methano-2H-pyrido[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-, dihydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● 2 HCl

RN 357425-89-9 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-, 7,8,9,10-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 357425-90-2 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 357425-92-4 CAPLUS
CN 6,10-Methano-2H-pyrazino[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 357425-93-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)


CM 1
CRN 69718-72-5
CMF C11 H13 N




CM 2
CRN 104-15-4
CMF C7 H8 O3 S



RN 357426-13-2 CAPLUS
CN 1,5-Methano-2H-3-benzazepin-2-one, 1,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 474024-49-2 CAPLUS
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepine, 3,5,6,7,8,9-hexahydro-2-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 474024-50-5 CAPLUS
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepine, 2-ethyl-3,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 474024-51-6 CAPLUS
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepine, 3,5,6,7,8,9-hexahydro-2-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 474024-52-7 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-3-methyl-

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 474024-58-3 CAPLUS
CN 5,9-Methano-5H-thiazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-7-(2,2,2-trifluoro-1-thioxoethyl)- (9CI) (CA INDEX NAME)



L22 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:695763 CAPLUS
DOCUMENT NUMBER: 137:210972
TITLE: Use of GABA_A inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin E for the treatment of cognitive disorders
INVENTOR(S): Villalobos, Anabella
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 50 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

no odp

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069948	A1	20020912	WO 2002-1B515	20020220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, HR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, PT, GB, GR, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NC, NO, NZ, OM, PW, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, Z, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AI, BE, CH, CY, DE, DK, ES, PT, FR, GB, GR, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1363606	A1	20031126	EP 2002-700509	20020220
R: AT, BE, CH, DE, DK, ES, PT, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, RO, MK, CY, AL, TR				
EE 200300422	A	20040216	EE 2003-422	20020220
BR 2002007802	A	20040309	BR 2002-7802	20020220
US 2002193360	A1	20021219	US 2002-83743	20020226
NO 200303821	A	20030910	NO 2003-3021	20030828
US 2004082555	A1	20040429	US 2003-727934	20031203
PRIORITY APPLN. INFO.:			US 2001-272566P	20010301
			WO 2002-1B515	20020220
			US 2002-83743	20020226

OTHER SOURCE(S): MARPAT 137:210972
AB A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal comprising administration of a GABA_A inverse agonist or a pharmaceutically acceptable salt thereof, and a nicotine receptor partial agonist, estrogen, selective estrogen receptor modulator or vitamin E are present in amounts that render the composition effective enhancing cognition or in the treatment of diseases of cognitive dysfunction including but not limited to Alzheimer's Disease (AD), mild cognitive impairment, age-related cognitive decline, vascular dementia, Parkinson's disease, Huntington's disease, memory impairment associated with depression or anxiety, schizophrenia, Down's syndrome, stroke, traumatic brain injury (TBI), AIDS associated dementia and attention deficit disorder. The method of using these compns. is also disclosed.

Aryl Fused Azapolycyclic Compounds

L22 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

1T 5918-72-5 249296-44-4 287973-26-6

287973-47-7 328055-77-2 328055-78-3

328055-79-4 328055-80-7 328055-81-8

328055-84-1 328055-85-2 328055-86-3

328055-87-9 328055-88-5 328055-89-6

328055-90-9 328055-92-1 328055-93-3

328055-95-4 328055-96-5 328055-97-6

328055-98-0 328055-66-2 357424-19-2

367511-27-3 367511-30-6 347531-36-4

RN PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of GABA_A inverse agonists in combination with nicotine receptor partial agonists or estrogen or selective estrogen modulators or vitamin E for treatment of cognitive disorders)


RN 69718-72-5 CAPLUS

CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 249296-44-4 CAPLUS

CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)



RN 287973-26-6 CAPLUS


CN 1,5-Methano-1H-3-benzazepine, 7,8-difluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 287973-27-7 CAPLUS


CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-ethynyl-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)

L22 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-81-8 CAPLUS

CN 1,5-Methano-1H-3-benzazepine, 7-ethynyl-8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-84-1 CAPLUS

CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)




RN 328055-85-2 CAPLUS

CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 328055-86-3 CAPLUS

CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro- (9CI) (CA INDEX NAME)




RN 328055-87-4 CAPLUS

CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-8-nitro- (9CI) (CA INDEX NAME)


L22 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 328055-77-2 CAPLUS

CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 328055-78-3 CAPLUS

CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)



RN 328055-79-4 CAPLUS

CN 5,9-Methanimidazo[4,5-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 328055-80-7 CAPLUS

CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)


L22 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

CN 5,9-Methanimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl- (9CI) (CA INDEX NAME)




RN 328055-88-5 CAPLUS

CN 5,9-Methanimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 328055-89-6 CAPLUS

CN 5,9-Methanimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl- (9CI) (CA INDEX NAME)



RN 328055-90-9 CAPLUS

CN 5,9-Methanimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl- (9CI) (CA INDEX NAME)




RN 328055-92-1 CAPLUS

CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-94-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-95-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-96-5 CAPLUS
CN Ethanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 328055-97-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



L22 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 367511-38-4 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-3(5H)-one, 6,7,8,9-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 328055-99-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328056-66-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 357424-19-2 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl- (9CI) (CA INDEX NAME)



RN 367511-27-1 CAPLUS
CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-3(5H)-one, 6,7,8,9-tetrahydro- (9CI) (CA INDEX NAME)



RN 367511-30-6 CAPLUS
CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-3(5H)-one, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)

L22 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:671909 CAPLUS

DOCUMENT NUMBER: 137:201144

TITLE: Sulfamide derivatives useful as β_3 agonists

INVENTOR(S): Dow, Robert Lee; Paight, Ernest Sidney, Jr.

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Eur. Pat. Appl., 41 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1236723	A1	20020904	EP 2002-251221	20020222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2002346982	A2	20021115	JP 2002-51109	20020227
US 2002128247	A1	20020912	US 2002-86588	20020228
BR 2002000626	A	20030715	BR 2002-626	20020301


PRIORITY APPLN. INFO.: US 2001-272681P P 20010301

OTHER SOURCE(S): MARPAT 137:201144

GI



I



II

AB Sulfaides $ROCHAR_2N(R_1CR_2R_3)CH_2CH_4NR_5SO_2NR_6R_7$ [Ar = (un)substituted aryl, heteroaryl; R = H, protective group; R1 = H, alkyl, protective group; R2, R3 = H, alkyl; R6, R7 = H, (un)substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl; NR6R7 = cyclic amino; X = bond, O, S(O), SO2, (un)substituted NH; in which the benzene ring may be further substituted by halogen, CN, (un)substituted alkyl, alkoxy] were prepared for use in the treatment of diseases dependent on the signaling pathways associated with β -adrenergic receptors, such as obesity, diabetes, hypertension, gastrointestinal hypo- or hyper-motility and cardiovascular diseases. Thus, 4-O2NC6H4CH2Me2NH2 was treated with (R)-3-chlorostyrene oxide, cyclized to the nitrophenylloxazolidinone, the nitro group reduced to amine, and treated with 1-piperidinesulfamoyl chloride to give the oxazolidinone I which was treated with KOH to give the title compound II. All the products showed selective β_3 -adrenergic

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

activity.

RN 454218-95-2 CAPLUS

CN 1,5-Methano-3H-3-benzazepine-3-sulfonamide, 1,2,4,5-tetrahydro-N-[4-[2-[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]aminoethylphenyl]-7-(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 454219-69-3 CAPLUS

CN 1,5-Methano-3H-3-benzazepine-3-sulfonamide, 1,2,4,5-tetrahydro-N-[4-[2-[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]aminoethylphenyl]-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



X L22 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

INVENTION NUMBER: 2002104621 CAPLUS

DOCUMENT NUMBER: 136145265

TITLE: A pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) comprising a nicotine receptor partial agonist and anti-ADHD agent

INVENTOR(S): Watsky, Eric Jacob; Coe, Jotham Wadsworth; Harrigan, Edmund Patrick; O'Neill, Brian Thomas; Sanda, Steven Bradley

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Eur. Pat. Appl., 19 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1177798	A2	20020206	EP 2001-306455	20010727
EP 1177798	A3	20030305		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
US 2002016334 A1 20020207 US 2001-865793 20010525
BR 2001003169 A 20020528 BR 2001-3169 20010731
JP 2002316949 A2 200201031 JP 2001-231554 20010731

PRIORITY APPN. INFO.: US 2000-221718P P 20000731
AB Pharmaceutical compns. are disclosed for the treatment of attention deficit hyperactivity disorder (ADHD). The pharmaceutical compnd.s are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an anti-ADHD agent and a pharmaceutically acceptable carrier. The method of using these compds. is also disclosed.

IT 69718-72-5 69718-72-5, isomers 230615-75-5 230615-75-5D, isomers 249296-44-4 249296-44-4D, isomers 287973-26-6D, isomers 287973-27-7 287973-27-7D, isomers 328055-77-2 328055-77-2D, isomers 328055-78-3 328055-78-3D, isomers 328055-79-4 328055-79-4D, isomers 328055-80-7 328055-80-7D, isomers 328055-81-8 328055-81-8D, isomers 328055-83-0 328055-83-0D, isomers 328055-85-2 328055-85-2D, isomers 328055-86-3 328055-86-3D, isomers 328055-87-4 328055-87-4D, isomers 328055-88-5 328055-88-5D, isomers 328055-89-6 328055-89-6D, isomers 328055-90-9 328055-90-9D, isomers 328055-92-1 328055-92-1D, isomers 328055-94-3 328055-94-3D, isomers 328055-95-4 328055-95-4D, isomers 328055-96-5 328055-96-5D, isomers 328055-97-6 328055-97-6D, isomers 328055-98-7 328055-98-7D, isomers 328055-99-8 328055-99-8D, isomers 328056-66-2 328056-66-2D, isomers 357424-19-2 357424-19-2D, isomers 357424-20-5 357424-20-5D, isomers

RI: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

L22 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(nicotine receptor partial agonist and anti-attention deficit hyperactivity disorder agent for pharmaceutical compn. for treatment of attention deficit hyperactivity disorder)

RN 69718-72-5 CAPLUS

CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 69718-72-5 CAPLUS

CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)



RN 69718-77-0 CAPLUS

CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)




RN 69718-77-0 CAPLUS

CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)





RN 230615-75-5 CAPLUS

CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 230615-75-5 CAPLUS


CN 1,5-Methano-1H-3-benzazepine, 7,8-difluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




L22 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)





RN 249296-44-4 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)



RN 249296-44-4 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)




RN 287973-26-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-difluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




Aryl Fused Azapolycyclic Compounds


L22 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-87-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl- (9CI) (CA INDEX NAME)



RN 328055-87-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl- (9CI) (CA INDEX NAME)




RN 328055-88-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 328055-88-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)


L22 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-89-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl- (9CI) (CA INDEX NAME)



RN 328055-89-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl- (9CI) (CA INDEX NAME)




RN 328055-90-9 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl- (9CI) (CA INDEX NAME)




RN 328055-90-9 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl- (9CI) (CA INDEX NAME)

L22 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-92-1 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl- (9CI) (CA INDEX NAME)




RN 328055-92-1 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl- (9CI) (CA INDEX NAME)



RN 328055-94-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-94-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-95-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)


L22 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-95-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-96-5 CAPLUS
CN Echanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)



RN 328055-96-5 CAPLUS
CN Echanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 328055-97-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-97-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-98-7 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine,
6,7,8,9-tetrahydro-3-methyl-
(9CI) (CA INDEX NAME)



RN 328055-98-7 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine,
6,7,8,9-tetrahydro-3-methyl-
(9CI) (CA INDEX NAME)




RN 328055-99-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-99-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)


L22 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328056-66-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-fluoro-2,3,4,5-tetrahydro-
(9CI) (CA INDEX NAME)




RN 328056-66-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-fluoro-2,3,4,5-tetrahydro-
(9CI) (CA INDEX NAME)



RN 357424-19-2 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl-
(9CI) (CA INDEX NAME)




RN 357424-19-2 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl-
(9CI) (CA INDEX NAME)




L22 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 357424-20-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro- (9CI)
(CA INDEX NAME)



RN 357424-20-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro- (9CI)
(CA INDEX NAME)



L22 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:885334 CAPLUS
DOCUMENT NUMBER: 136:658
TITLE: A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss, comprising a nicotine receptor partial agonist and an anti-obesity agent

INVENTOR(S): Coe, Joathan W.; O'Neill, Brian T.; Sands, Steven B.; Dow, Robert L. B.; Harrigan, Edmund P.; Watsky, Eric J.

PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1159970	A2	20011205	EP 2001-304806	20010531
EP 1159970	A3	20030305	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO	
US 2002010192	A1	20020124	US 2001-850042	20010507
BR 2001002211	A	20020305	BR 2001-2211	20010530
JP 2002012558	A2	20020115	JP 2001-164010	20010531
US 2003176457	A1	20030918	US 2003-366532	20030213

PRIORITY APPLN. INFO.: US 2000-2088567 P 20000602
US 2001-850042 B1 20010507

AB Pharmaceutical compns. are disclosed for the treatment of obesity, an overweight condition and compulsive overeating. The pharmaceutical compns. are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an anti-obesity agent or weight loss

facilitator or promoter, such as Xenical and Meridia, and a pharmaceutically acceptable carrier. The nicotine receptor partial agonist and an anti-obesity agent or weight loss facilitator are administered

substantially simultaneously. A method of treating a disorder or condition in which obesity or an overweight condition predominates, including type 2 diabetes mellitus, hypertension, dyslipidemias, and increased mortality in a mammal comprises administering a composition containing

nicotine receptor partial agonist and an anti-obesity agent.

IT 69718-72-5 230615-75-4 249294-44-4
287973-26-6 287973-27-7 328055-77-2
328055-78-3 328055-79-4 328055-80-7
328055-81-0 328055-83-0 328055-84-1
328055-85-2 328055-86-3 328055-87-4
328055-88-5 328055-89-6 328055-90-9
328055-92-1 328055-94-3 328055-95-4
328055-96-5 328055-97-6 328055-98-7
328055-99-8 328056-66-2 357424-19-2

357424-20-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising nicotine receptor partial agonist and antiobesity agent for treatment of obesity and related disorders)


RN 69718-72-5 CAPLUS

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 230615-75-5 CAPLUS
 CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 249296-44-4 CAPLUS
 CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)




RN 287973-26-6 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7,8-difluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 287973-27-7 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile,
 8-ethynyl-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)


L22 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-81-8 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7-ethynyl-8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-83-0 CAPLUS
 CN 5,9-Methano-2H-isothiazolo[4,5-h][3]benzazepine, 3,5,6,7,8,9-hexahydro-2-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 328055-84-1 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)




RN 328055-85-2 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)




L22 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-77-2 CAPLUS
 CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 328055-78-3 CAPLUS
 CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 328055-79-4 CAPLUS
 CN 5,9-Methanimidazo[4,5-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 328055-80-7 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)


L22 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 328055-86-3 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro- (9CI) (CA INDEX NAME)




RN 328055-87-4 CAPLUS
 CN 5,9-Methanimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl- (9CI) (CA INDEX NAME)



RN 328055-88-5 CAPLUS
 CN 5,9-Methanimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 328055-89-6 CAPLUS
 CN 5,9-Methanimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl- (9CI) (CA INDEX NAME)




RN 328055-90-9 CAPLUS
 CN 5,9-Methanimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds

L22 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 328055-92-1 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl- (9CI) (CA INDEX NAME)




RN 328055-94-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-95-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-96-5 CAPLUS
CN Ethanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)



L22 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 357424-20-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro- (9CI) (CA INDEX NAME)



L22 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

ACCESSION NUMBER: 2001:864711 CAPLUS
DOCUMENT NUMBER: 136:11124
TITLE: Reactive crystallization method to improve particle size
INVENTOR(S): Am Ende, David Jon; Crawford, Thomas Charles; Weston, Neil Philip
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 11 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1157726	A1	20011128	EP 2001-30442	20010518
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BG 105518	A	20011231	BG 2001-105518	20010517
JP 2002028475	A2	20020129	JP 2001-153592	20010523
US 2002016498	A1	20020207	US 2001-863492	20010523
US 6558435	B2	20030506		
ZA 2001004207	A	20021125	ZA 2001-4207	20010523
TR 200101453	A2	20011221	TR 2001-20010145320010524	
HR 2001000399	A1	20021231	HR 2001-399	20010524
NO 2001002571	A	20011127	NO 2001-2571	20010525
CN 1326803	A	20011219	CN 2001-119055	20010525
EE 200100284	A	20020215	EE 2001-284	20010525
BR 200102129	A	20020521	BR 2001-2129	20010525
NZ 511966	A	20021126	NZ 2001-511966	20010525
SG 96223	A1	20030523	SG 2001-3136	20010525

PRIORITY APPLN. INFO.: US 2000-207629P, P 20000526
AB This invention provides a method of conducting a simultaneous chemical reaction and controlled crystallization of the product employing impinging fluid jet streams containing reactants capable of producing the product with desired particle size characteristics. An example is given for reaction and crystallization of ziprasidone to achieve the desired ziprasidone-HCl·H₂O.
IT 249296-44-4
RL: PRP (Properties); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(reactive crystallization method to improve particle size)
RN 249296-44-4 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)



IT 375815-87-5P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);

Aryl Fused Azapolycyclic Compounds

L22 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 BIOL (biological study); PREP (Preparation); USES (Uses).
 (reactive crystn. method to improve particle size)

RN 375815-87-5 CAPLUS
 CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-,
 (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)


CM 1
 CRN 249296-44-4
 CMP C13 H13 N3



CM 2

CRN 87-69-4
 CMP C4 H6 O6

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L22 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
 2001-798758 CAPLUS
 135:339282
 Nicotinic receptor partial agonist, cholinesterase inhibitor, and estrogenic agent composition for treatment of diseases of cognitive dysfunction in a mammal

INVENTOR(S): Coe, Jotham Wadsworth; Sands, Steven Bradley; Harrigan, Edmund Patrick; O'Neill, Brian Thomas; Watsky, Eric Jacob

PATENT ASSIGNEE(S): USA U.S. Pat. Appl. Publ., 20 pp.
 SOURCE: CODEN: USXXCO

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001036949	A1	20011101	US 2001-760966	20010116
WO 2001085145	A2	20011115	WO 2001-IB681	20010424
WO 2001085145	A3	20020613		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, UW, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GR, GR, IE, IT, LU, MC, NL, PT, SE, BE, CH, CY, BJ, CP, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1280554 A2 20030205 EP 2001-921733 20010424

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR 2001010487 A 20030401 BR 2001-10487 20010424

JP 2003532670 T2 20031105 JP 2001-581799 20010424

US 2003130303 A1 20030710 US 2003-347955 20030121

PRIORITY APPN. INFO.: US 2000-2027999 P 20000509

US 2001-760966 B1 20010116

WO 2001-IB681 W 20010424

AB A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal comprising administration of a nicotine receptor partial agonist or a pharmaceutically acceptable salt thereof; and an acetylcholinesterase inhibitor, butylcholinesterase inhibitor, an estrogenic agent, selective estrogen receptor modulator or muscarinic agonist or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The nicotine receptor partial agonist and acetylcholinesterase inhibitor, butylcholinesterase inhibitor, estrogen, selective estrogen receptor modulator or muscarinic agonist are present in amounts that render the composition effective enhancing cognition or in the treatment of diseases of cognitive dysfunction including but not limited to Alzheimer's Disease, mild cognitive impairment, age-related

ABN

L22 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 cognitive decline, vascular dementia, Parkinson's disease dementia, Huntington's Disease, Stroke, TBI, AIDS assoc'd. dementia and schizophrenia. The method of using these compns. is also disclosed.


IT 69718-72-5 230615-75-5 249296-44-4
 207973-26-6 287973-27-7 328055-77-2
 328055-78-3 328055-79-4 328055-80-7
 328055-81-8 328055-83-0 328055-84-1
 328055-85-2 328055-86-3 328055-87-4
 328055-88-5 328055-89-6 328055-90-9
 328055-92-1 328055-94-3 328055-95-4
 328055-96-5 328055-97-6 328055-98-7
 328055-99-8 328056-66-2 357424-19-2
 357424-20-5

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses).
 (nicotinic receptor partial agonist, cholinesterase inhibitor, and estrogenic agent composition for treatment of diseases of cognitive dysfunction in a mammal)

RN 69718-72-5 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 230615-75-5 CAPLUS
 CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 249296-44-4 CAPLUS
 CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)




RN 287973-26-6 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7,8-difluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)


L22 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 287973-27-7 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile,
 8-ethynyl-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-77-2 CAPLUS
 CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one,
 3,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 328055-78-3 CAPLUS
 CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 328055-79-4 CAPLUS
 CN 5,9-Methanimidazo[4,5-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




Aryl Fused Azapolycyclic Compounds


L22 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 328055-80-7 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-81-8 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7-ethynyl-8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-83-0 CAPLUS
 CN 5,9-Methano-2H-isothiazolo[4,5-h][3]benzazepine, 3,5,6,7,8,9-hexahydro-2-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 328055-84-1 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)




RN 328055-85-2 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-90-9 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl- (9CI) (CA INDEX NAME)




RN 328055-92-1 CAPLUS
 CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl- (9CI) (CA INDEX NAME)




RN 328055-94-3 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-95-4 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




L22 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-86-3 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro- (9CI) (CA INDEX NAME)



RN 328055-87-4 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl- (9CI) (CA INDEX NAME)




RN 328055-88-5 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 328055-89-6 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl- (9CI) (CA INDEX NAME)


L22 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 328055-96-5 CAPLUS
 CN Ethanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 328055-97-6 CAPLUS
 CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-98-7 CAPLUS
 CN 5,9-Methano-5H-isoxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)



RN 328055-99-8 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328056-66-2 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




Aryl Fused Azapolycyclic Compounds


L22 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 357424-19-2 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl- (9CI) (CA INDEX NAME)



RN 357424-20-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro- (9CI) (CA INDEX NAME)




L22 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001-762800 CAPLUS
DOCUMENT NUMBER: 135332726
TITLE: A pharmaceutical composition containing a nicotine receptor agonist and an analgesic for treatment of acute, chronic pain and/or neuropathic pain and migraines
INVENTOR(S): Cee, Jotham Wadsworth; Harrigan, Edmund Patrick; O'Neill, Brian Thomas; Sande, Steven Bradley; Watsky, Eric Jacob
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIIXAD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2001076576	A2	20011018	WO 2001-IB391	20010316	
WO 2001076576	A3	20030620			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KW, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VN, YU, ZA, ZM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RN: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, 2W, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BP, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MU, NE, SN, TD, TG				
US 2001036943	A1	20011101	US 2000-740307	200001218	
EP 1272218	A2	20030108	EP 2001-910097	20010316	
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001009837	A	20020121	BR 2001-9837	20010316
	JP 2003530245	T2	20031014	JP 2001-574094	20010316
	BG 107138	A	20030530	BG 2002-107138	20020923
	US 2003133951	A1	20030717	US 2003-348381	20030121
PRIORITY APPLN. INFO.:			US 2000-195718P	P 20000407	
			US 2000-740307	B1 200001218	
			WO 2001-IB391	W 20010316	


AB Oral, parenteral or transdermal compns. are disclosed for the treatment of acute, chronic and/or neuropathic pain. The pharmaceutical compns. are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an analgesic agent and a pharmaceutically acceptable carrier. The analgesic agent is selected from opioid analgesics, NMDA antagonists, substance P antagonists, COX 1 and COX 2 inhibitors, tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRI), capsaicin receptor agonists, anesthetic agents, benzodiazepines, skeletal muscle relaxants, migraine therapeutic agents, anticonvulsants, antihypertensives, antiarrhythmics, antihistamines, steroids, caffeine, N-type calcium channel antagonists and botulinum toxin. The method of using these compds. and a method of treating acute, chronic and/or neuropathic pain and migraine in a mammal including a human

human


L22 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-77-2 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 328055-78-3 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)



RN 328055-79-4 CAPLUS
CN 5,9-Methanimidazo[4,5-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)



RN 328055-80-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-81-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-ethynyl-8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)

L22 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

ie also disclosed.

IT 69718-72-5 249296-44-4 287973-26-6
287973-27-7 328055-77-2 328055-78-3
328055-79-4 328055-80-7 328055-81-8
328055-83-0 328055-84-1 328055-85-2
328055-86-3 328055-87-4 328055-88-5
328055-89-6 328055-90-9 328055-92-1
328055-94-3 328055-95-4 328055-96-5
328055-97-6 328055-99-8 328055-66-2
357424-19-2 367511-27-1 367511-30-6
367511-38-4


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(Uses) (compns. containing nicotine receptor agonist and analgesic for treatment of acute, chronic pain and/or neuropathic pain and migraines)


RN 69718-72-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 249296-44-4 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)




RN 387973-26-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-difluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 287973-27-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-ethynyl-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(CA INDEX NAME)



RN 328055-83-0 CAPLUS
CN 5,9-Methano-2H-imothiazolo[4,5-h][3]benzazepine, 3,5,6,7,8,9-hexahydro-2-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 328055-84-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)




RN 328055-85-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro- (9CI) (CA INDEX NAME)




RN 328055-86-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro- (9CI) (CA INDEX NAME)


L22 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-92-1 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl- (9CI) (CA INDEX NAME)




RN 328055-94-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-95-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-96-5 CAPLUS
CN Ethanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 328055-97-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)


L22 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-87-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl- (9CI) (CA INDEX NAME)



RN 328055-88-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 328055-89-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl- (9CI) (CA INDEX NAME)




RN 328055-90-9 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl- (9CI) (CA INDEX NAME)


L22 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-99-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328056-66-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 357424-19-2 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl- (9CI) (CA INDEX NAME)




RN 367511-27-1 CAPLUS
CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-3(SH)-one, 6,7,8,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 367511-30-6 CAPLUS

Aryl Fused Azapolycyclic Compounds

L22 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-3(SH)-one, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 367511-38-4 CAPLUS
 CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(SH)-one, 6,7,8,9-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)



L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 such as I [R1 = H, alkyl, unconjugated alkenyl, benzyl, X(CO)R13, CH2CH2O-alkyl; R2, R3 = H, alkenyl, alkynyl, hydroxy, nitro, amino, halo, cyano, SOalkyl, (q = 0 - 2), alkylamino, CO2R4, CONRS5, SO2NR7R8, COR13,

X(CO)R13; R2 and R3, together with the carbons to which they are attached form a 4-7 membered monocyclic ring or a 10-14 membered bicyclic ring; R4-R8, R13 = H, alkyl or R5 and R6, or R7 and R8 together with nitrogen to which they are attached, form a pyrrolidine, piperidine, morpholine, azetidine, piperazine, thiomorpholine; X = alkylene], and their pharmaceutically acceptable salts, as nicotine binding inhibitors (IC50 < 10 μ M) in the treatment of neural. and psychol. disorders. Thus, aryl-fused azapolycyclic compd. I (R1-R3 = H) was prep'd. via a multistep synthetic sequence starting from 2-fluorobromobenzene via a cycloaddn. with cyclopentadiene and an amination with triethylbenzylammonium chloride.

IT 230615-08-4P 328055-86-3P 328055-99-8P


357424-19-2P 357424-20-5P

RL: BAU (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of aryl-fused azapolycyclic compds. as nicotine binding inhibitor)

RN 230615-08-4 CAPLUS

CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7,8-dinitro- (9CI) (CA INDEX NAME)




RN 328055-86-3 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro- (9CI) (CA INDEX NAME)

RN 328055-99-8 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)

*Applicant**


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2001-636053 CAPLUS
 DOCUMENT NUMBER: 135:210949
 TITLE: Preparation of aryl-fused azapolycyclic compounds as nicotine binding inhibitors
 INVENTOR(S): Brook, Paige Roanne Palmer; Coe, Jotham Wadsworth
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 110 pp.
 CODEN: PIAXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001062736	A1	20010830	WO 2001-IB153	20010208
N: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, ES, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GR, IE, IT, LU, MC, NL, PT, SE, TR, BP, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6605610	B1	20030812	US 2000-514003	20000225
BR 2001008610	A	20021119	BR 2001-8610	20010208
EP 1259489	A1	20021217	EP 2001-953430	20010208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003524002	T2	20030812	JP 2001-562516	20010208
EE 200200475	A	20031215	EE 2002-475	20010208
BG 106908	A	20030430	BG 2002-106908	20020705
NO 2002004042	A	20021017	NO 2002-4042	20020823
PRIORITY APPLN. INFO.:				
US 2000-514002	A	20000225		
US 1997-70245P	P	19971231		
WO 1998-IB1813	A2	19981113		
US 1999-402010	A2	19990928		
WO 2001-IB153	W	20010208		
OTHER SOURCE(S): MARPAT 135:210949				
GI				




AB The invention discloses the preparation of aryl-fused azapolycyclic compds.,


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 357424-19-2 CAPLUS
 CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl- (9CI) (CA INDEX NAME)



RN 357424-20-5 CAPLUS
 CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro- (9CI) (CA INDEX NAME)



IT 69718-72-5P	230614-99-0P	230615-00-6P
230615-01-7P	230615-02-8P	230615-03-8P
230615-04-0P	230615-05-1P	230615-06-2P
230615-07-3P	230615-09-5P	230615-10-8P
230615-11-9P	230615-12-0P	230615-13-1P
230615-14-2P	230615-15-3P	230615-16-4P
230615-17-5P	230615-18-6P	230615-19-7P
230615-20-0P	230615-21-1P	230615-22-2P
230615-23-3P	230615-24-4P	230615-25-5P
230615-26-6P	230615-27-7P	230615-28-8P
230615-29-9P	230615-30-2P	230615-31-3P
230615-32-4P	230615-33-5P	230615-34-6P
230615-35-7P	230615-36-8P	230615-37-9P
230615-38-0P	230615-39-1P	230615-40-4P
230615-41-5P	230615-42-6P	230615-43-7P
230615-44-8P	230615-45-9P	230615-46-0P
230615-75-5P	249296-44-4P	287973-24-4P
287973-25-5P	287973-26-6P	287973-27-7P
287973-28-0P	287973-29-9P	287973-32-4P
328055-77-2P	328055-78-3P	328055-79-4P
328055-80-7P	328055-81-8P	328055-84-1P
328055-85-2P	328055-87-4P	328055-88-5P
328055-89-6P	328055-90-9P	328055-92-1P
328055-94-3P	328055-95-4P	328055-96-5P
328055-97-6P	328055-98-7P	328056-66-2P
357424-02-3P	357424-03-4P	357424-04-5P
357424-05-6P	357424-06-7P	357424-07-8P

Aryl Fused Azapoly(cyclic Compounds)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


- 357424-08-9P 357424-09-0P 357424-10-2P
 357424-11-4P 357424-12-5P 357424-13-6P
 357424-14-7P 357424-15-8P 357424-16-9P
 357424-17-0P 357424-18-1P 357424-19-2P
 357424-20-3P 357424-21-4P 357424-22-5P
 357424-23-6P 357424-24-7P 357424-25-8P
 357424-26-9P 357424-27-1P 357424-28-2P
 357424-29-3P 357424-30-4P 357424-31-5P
 357424-32-6P 357424-33-7P 357424-34-8P
 357424-35-9P 357424-36-10P 357424-37-11P
 357424-38-12P 357424-39-13P 357424-40-14P
 357424-41-15P 357424-42-16P 357424-43-17P
 357424-44-18P 357424-45-19P 357424-46-20P
 357424-47-21P 357424-48-22P 357424-49-23P
 357424-50-24P 357424-51-25P 357424-52-26P
 357424-53-27P 357424-54-28P 357424-55-29P
 357424-56-30P 357424-57-31P 357424-58-32P
 357424-59-33P 357424-60-34P 357424-61-35P
 357424-62-36P 357424-63-37P 357424-64-38P
 357424-65-39P 357424-66-40P 357424-67-41P
 357424-68-42P 357424-69-43P 357424-70-44P
 357424-71-45P 357424-72-46P 357424-73-47P
 357424-74-48P 357424-75-49P 357424-76-50P
 357424-77-51P 357424-78-52P 357424-79-53P
 357424-80-54P 357424-81-55P 357424-82-56P
 357424-83-57P 357424-84-58P 357424-85-59P
 357424-86-60P 357424-87-61P 357424-88-62P
 357424-89-63P 357424-90-64P 357424-91-65P
 357424-92-66P 357424-93-67P 357424-94-68P
 357424-95-69P 357424-96-70P 357424-97-71P
 357424-98-72P 357425-00-4P 357425-01-5P
 357425-02-6P 357425-03-7P 357425-04-8P 357425-05-9P
 357425-06-10P 357425-07-11P 357425-08-12P
 357425-13-14P 357425-15-16P 357425-17-18P
 357425-19-19P 357425-20-20P 357425-21-21P
 357425-22-22P 357425-23-23P 357425-24-24P
 357425-25-25P 357425-26-26P 357425-27-27P
 357425-28-28P 357425-29-29P 357425-30-30P
 357425-31-31P 357425-32-32P 357425-33-33P
 357425-34-34P 357425-35-35P 357425-36-36P
 357425-37-37P 357425-38-38P 357425-39-39P
 357425-40-40P 357425-41-41P 357425-42-42P
 357425-43-43P 357425-44-44P 357425-45-45P
 357425-46-46P 357425-47-47P 357425-48-48P
 357425-49-49P 357425-50-50P 357425-51-51P
 357425-52-52P 357425-53-53P 357425-54-54P
 357425-55-55P 357425-56-56P 357425-57-57P
 357425-58-58P 357425-59-59P 357425-60-60P
 357425-61-61P 357425-62-62P 357425-63-63P
 357425-64-64P 357425-65-65P 357425-66-66P
 357425-67-67P 357425-68-68P 357425-69-69P
 357425-70-70P 357425-71-71P 357425-72-72P
 357425-73-73P 357425-74-74P 357425-75-75P
 357425-76-76P 357425-77-77P 357425-78-78P
 357425-79-79P 357425-80-80P 357425-81-81P
 357425-82-82P 357425-83-83P 357425-84-84P
 357425-85-85P 357425-86-86P 357425-87-87P

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


- (prepn. of aryl-fused azapoly(cyclic compd. as nicotine binding inhibitor))
 RN 69718-72-5 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



- RN 230614-99-0 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



- HCl
 RN 230615-00-6 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-methyl-, hydrochloride (9CI) (CA INDEX NAME)




- RN 230615-01-7 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)



RL=BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPA (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



● HCl

- RN 230615-02-8 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


- RN 230615-03-9 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 6-fluoro-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

- RN 230615-04-0 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

- RN 230615-05-1 CAPLUS
 CN 1,5-Methano-1H-3-benzazepin-7-amine, 2,3,4,5-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

- RN 230615-06-2 CAPLUS
 CN Acetamide, N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

- RN 230615-07-3 CAPLUS
 CN 5,9-Methano-5H-thiazolo[4,5-h] (3)benzazepine, 6,7,8,9-tetrahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




Aryl Fused Azapolycyclic Compounds

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-09-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-, propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-10-8 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-11-9 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-15-3 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-butyl-1,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-16-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-17-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-12-0 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-13-1 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-14-2 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-propyl-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-18-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-19-7 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-20-0 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-1,5,6,7,8,9-hexahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-21-1 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-22-2 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-, 1,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-23-3 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-27-7 CAPLUS
CN Benzamide, 2-fluoro-N-(2,3,4,5-tetrahydro-8-hydroxy-1,5-methano-1H-3-benzazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-28-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-29-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-24-4 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-25-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-26-6 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-30-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(5-methyl-1,2,4-oxadiazol-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-31-3 CAPLUS
CN Ethanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-32-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-33-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine,
6,7,8,9-tetrahydro-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-34-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine,
2,3,4,5-tetrahydro-7-(1-methyl-1H-pyrazol-5-
yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-35-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine,
2,3,4,5-tetrahydro-7-(1-methyl-1H-pyrazol-3-

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
y1)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-36-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro-,
hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-37-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N,N-
dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-38-0 CAPLUS
CN Pyrrolidine, 1-[(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-
yl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-39-1 CAPLUS
CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-40-4 CAPLUS
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one, 3,5,6,7,8,9-hexahydro-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-41-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-phenyl-, hydrochloride
(9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-42-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-6-ol, 2,3,4,5-tetrahydro-, hydrochloride
(9CI) (CA INDEX NAME)



● HCl

RN 230615-43-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-difluoro-2,3,4,5-tetrahydro-,
hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-44-8 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 2-ethyl-6,7,8,9-tetrahydro-,
monohydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-45-9 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-46-0 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-75-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 249296-44-4 CAPLUS
CN 6,10-Methano-6H-pyrazolo[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)



RN 287973-24-4 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepine-1,3(2H,5H)-dione, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 287973-25-5 CAPLUS
CN 5,9-Methanimidazo[4,5-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro-1,3-dimethyl- (9CI) (CA INDEX NAME)




RN 287973-26-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-difluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 287973-27-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-ethynyl-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 287973-28-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro-8-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 287973-29-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro-8-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 287973-32-4 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepine-1,3(2H,5H)-dione, 5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)




L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 328055-77-2 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 328055-78-3 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)



RN 328055-79-4 CAPLUS
CN 5,9-Methanimidazo[4,5-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 328055-80-7 CAPLUS
CN 5,9-Methanimidazo[4,5-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)



RN 328055-81-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-ethynyl-8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-84-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)



RN 328055-85-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 328055-87-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl- (9CI) (CA INDEX NAME)




RN 328055-88-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-89-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl- (9CI) (CA INDEX NAME)



RN 328055-90-9 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl- (9CI) (CA INDEX NAME)




RN 328055-92-1 CAPLUS
CN 6,10-Methano-6H-pyrazolo[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl- (9CI) (CA INDEX NAME)




RN 328055-94-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-95-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-96-5 CAPLUS
CN Ethanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)



RN 328055-97-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-98-7 CAPLUS
CN 5,9-Methano-5H-thieno[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)




L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 328056-66-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-02-3 CAPLUS
CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)



RN 357424-03-4 CAPLUS
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 357424-04-5 CAPLUS
CN Benzamide, N-(2,3,4,5-tetrahydro-8-hydroxy-1,5-methano-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 357424-05-6 CAPLUS
CN 5,9-Methano-5H-thieno[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-06-7 CAPLUS
CN 5,9-Methano-5H-thieno[2,3-h][3]benzazepin-3-amine,
6,7,8,9-tetrahydro-N,N-dimethyl-1,1-dioxide (9CI) (CA INDEX NAME)



RN 357424-07-8 CAPLUS
CN 6,10-Methano-1H-pyrazino[2,3-h][3]benzazepine-2,3-dione,
4,6,7,8,9,10-hexahydro- (9CI) (CA INDEX NAME)




RN 357424-08-9 CAPLUS
CN 6,10-Methano-1H-pyrazino[2,3-h][3]benzazepine-2,3-dione,
4,6,7,8,9,10-hexahydro-1,4-dimethyl- (9CI) (CA INDEX NAME)




RN 357424-09-0 CAPLUS
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one,
3,5,6,7,8,9-hexahydro-3-


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
methyl- (9CI) (CA INDEX NAME)




RN 357424-10-3 CAPLUS
CN 5,9-Methano-5H-thieno[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-
(9CI) (CA INDEX NAME)



RN 357424-11-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine,
1,5,6,7,8,9-hexahydro-2-methyl-1-propyl- (9CI) (CA INDEX NAME)




RN 357424-12-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro- (9CI)
(CA INDEX NAME)




RN 357424-13-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-propyl-
(9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-18-1 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-
1,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 357424-21-6 CAPLUS
CN 6,10-Methano-2H-pyrazino[2,3-h][3]benzazepin-2-one,
1,5,6,7,8,9,10-hexahydro-
(9CI) (CA INDEX NAME)



RN 357424-22-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-amine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-23-8 CAPLUS
CN Acetamide, N-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)- (9CI)
(CA INDEX NAME)




Aryl Fused Azapolycyclic Compounds

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 357424-24-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(5-methyl-1,2,4-oxadiazol-3-yl)- (9CI) (CA INDEX NAME)




RN 357424-25-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 357424-26-1 CAPLUS
CN Pyrrolidine, 1-[(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 357424-27-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-chloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-28-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-8-ethynyl-2,3,4,5-tetrahydro- (9CI)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 357424-34-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 6-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-36-3 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-37-4 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 357424-39-6 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)




L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(CA INDEX NAME)




RN 357424-29-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro-8-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 357424-30-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-ethynyl-2,3,4,5-tetrahydro-8-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 357424-31-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7,8-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 357424-32-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 357424-41-0 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 3-ethyl-7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-43-2 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-4-methyl- (9CI) (CA INDEX NAME)



RN 357424-45-4 CAPLUS
CN 6,10-Methano-2H-pyrido[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro- (9CI) (CA INDEX NAME)



RN 357424-47-6 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-49-8 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methoxy- (9CI) (CA INDEX NAME)




Aryl Fused Azapolycyclic Compounds


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-51-2 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-5-fluoro-7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)



RN 357424-53-4 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-11-fluoro-7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-55-6 CAPLUS
CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro-, (+)- (9CI) (CA INDEX NAME)



RN 357424-57-8 CAPLUS
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one, 3,5,6,7,8,9-hexahydro-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-59-0 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-61-4 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 357424-62-5 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 357424-63-6 CAPLUS
CN 5,9-Methano-5H-thieno[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, 1,1-dioxide, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-64-7 CAPLUS
CN 5,9-Methano-5H-thieno[2,3-h][3]benzazepin-3-amine, 6,7,8,9-tetrahydro-N,N-dimethyl-, 1,1-dioxide, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 357424-65-8 CAPLUS
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one, 3,5,6,7,8,9-hexahydro-3-methyl-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 357424-66-9 CAPLUS
CN Ethanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-67-0 CAPLUS
CN 5,9-Methano-5H-thieno[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-68-1 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-propyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 357424-69-2 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-70-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl-, (+)- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Rotation (+).




RN 357424-71-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-propyl-,
(+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 357424-72-7 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-butyl-1,5,6,7,8,9-hexahydro-,
(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 357424-73-8 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine,
1,5,6,7,8,9-hexahydro-2-methyl-1-
(2-methylpropyl)-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-77-2 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-
1,5,6,7,8,9-hexahydro-2-methyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-78-3 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-, (+)-
(9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-79-4 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine,
6,7,8,9-tetrahydro-2-methyl-,
(+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-80-7 CAPLUS

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-74-9 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-phenyl-,
(+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-75-0 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine,
1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-76-1 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-
1,5,6,7,8,9-hexahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-81-8 CAPLUS
CN 6,10-Methano-2H-pyrazino[2,3-h][3]benzazepin-2-one,
1,6,7,8,9,10-hexahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-82-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-methyl-, (+)- (9CI)
(CA INDEX NAME)

Rotation (+).



RN 357424-83-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro-, (+)- (9CI)
(CA INDEX NAME)

Rotation (+).




Aryl Fused Azapolycyclic Compounds

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 357424-84-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-amine, 2,3,4,5-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-85-2 CAPLUS
CN Acetamide, N-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 357424-86-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 357424-87-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(5-methyl-1,2,4-oxadiazol-3-yl)-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile,


8-fluoro-2,3,4,5-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-92-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-ethynyl-8-fluoro-2,3,4,5-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-93-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-ethynyl-2,3,4,5-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-94-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-chloro-2,3,4,5-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-88-5 CAPLUS
CN 1,5-Methano-2H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-89-6 CAPLUS
CN 1,5-Methano-2H-3-benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N,N-dimethyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 357424-90-9 CAPLUS
CN Pyrrolidine, 1-[(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)sulfonyl]-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 357424-91-0 CAPLUS


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 357424-95-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-96-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro-8-(trifluoromethyl)-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-97-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro-8-(trifluoromethyl)-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 357424-98-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro-8-(trifluoromethyl)-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-99-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-ethynyl-2,3,4,5-tetrahydro-8-

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 (trifluoromethyl)-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357425-00-4 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-(trifluoromethyl)-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 357425-02-6 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(trifluoromethyl)-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357425-03-7 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 6-fluoro-2,3,4,5-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

(Continued)




RN 357425-04-8 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357425-05-9 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 357425-07-1 CAPLUS
 CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 357425-09-3 CAPLUS
 CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methyl-


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 , (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357425-10-6 CAPLUS
 CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-3-methyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357425-12-8 CAPLUS
 CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 3-ethyl-7,8,9,10-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 357425-13-9 CAPLUS
 CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-4-methyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357425-15-1 CAPLUS

Page 56


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357425-17-3 CAPLUS
 CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-7,8,9,10-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357425-18-4 CAPLUS
 CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methoxy-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 357425-20-8 CAPLUS
 CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-5-fluoro-7,8,9,10-tetrahydro-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



Aryl Fused Azapolycyclic Compounds


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 357425-22-0 CAPLUS
 CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-11-fluoro-7,8,9,10-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357425-24-2 CAPLUS
 CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 357425-26-4 CAPLUS
 CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one, 3,5,6,7,8,9-hexahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 357425-27-5 CAPLUS
 CN Benzamide, 2-fluoro-N-(2,3,4,5-tetrahydro-8-hydroxy-1,5-methano-1H-3-benzazepin-7-yl)-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 357425-31-1 CAPLUS
 CN 5,9-Methano-5H-thieno[2,3-h][3]benzazepin-3-amine, 6,7,8,9-tetrahydro-N,N-dimethyl-, 1,1-dioxide, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-32-2 CAPLUS
 CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one, 3,5,6,7,8,9-hexahydro-3-methyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 357425-33-3 CAPLUS
 CN Ethanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-34-4 CAPLUS
 CN 5,9-Methano-5H-thieno[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357425-28-6 CAPLUS
 CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-2-methyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-29-7 CAPLUS
 CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-30-0 CAPLUS
 CN 5,9-Methano-5H-thieno[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, 1,1-dioxide, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357425-35-5 CAPLUS
 CN 5,9-Methimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-propyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-36-6 CAPLUS
 CN 5,9-Methimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 357425-37-7 CAPLUS
 CN 5,9-Methimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-38-8 CAPLUS

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-propyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-39-9 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-butyl-1,5,6,7,8,9-hexahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-40-2 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-(2-methylpropyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-41-3 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-phenyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-45-7 CAPLUS
 CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-46-8 CAPLUS
 CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-47-9 CAPLUS
 CN 5,9-Methano-5H-isoxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-48-0 CAPLUS

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357425-42-4 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 357425-43-5 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-44-6 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN 6,10-Methano-2H-pyrazino[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-49-1 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-methyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-50-4 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 357425-51-5 CAPLUS
 CN 1,5-Methano-1H-3-benzazepin-7-amine, 2,3,4,5-tetrahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-52-6 CAPLUS
 CN Acetamide, N-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)-, (-)-

Aryl Fused Azapolycyclic Compounds

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


(9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-53-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro-, (-)- (9CI)
(CA INDEX NAME)

Rotation (-).




RN 357425-54-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(5-methyl-1,2,4-oxadiazol-3-yl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-55-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357425-60-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile,
8-ethynyl-2,3,4,5-tetrahydro-,
(-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-61-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile,
8-chloro-2,3,4,5-tetrahydro-,
(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 357425-62-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-8-ethynyl-2,3,4,5-tetrahydro-,
(-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-63-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro-8-(trifluoromethyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 357425-56-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N,N-dimethyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-57-1 CAPLUS
CN Pyrrolidine, 1-[{2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl}sulfonyl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 357425-58-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile,
8-fluoro-2,3,4,5-tetrahydro-,
(-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 357425-59-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-ethynyl-8-fluoro-2,3,4,5-tetrahydro-,
(-)- (9CI) (CA INDEX NAME)


Rotation (-).

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357425-64-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro-8-(trifluoromethyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-65-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro-8-(trifluoromethyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 357425-66-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-ethynyl-2,3,4,5-tetrahydro-8-(trifluoromethyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-67-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-(trifluoromethyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357425-68-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(trifluoromethyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-69-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 6-fluoro-2,3,4,5-tetrahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-70-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357425-75-3 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 3-ethyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-76-4 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-4-methyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 357425-77-5 CAPLUS
CN 6,10-Methano-2H-pyrido[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 357425-78-6 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).

Page 60


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 357425-71-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-72-0 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 357425-73-1 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-74-2 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-3-methyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Rotation (-).




RN 357425-79-7 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methoxy-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-80-0 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-5-fluoro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 357425-81-1 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-11-fluoro-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 357425-82-2 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-, (-)- (9CI) (CA INDEX NAME)


Aryl Fused Azapoly cyclic Compounds

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 357425-83-3 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine,
7,8,9,10-tetrahydro-2-methyl-,
dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 357425-84-4 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine,
7,8,9,10-tetrahydro-3-methyl-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 357425-86-6 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine,
3-ethyl-7,8,9,10-tetrahydro-,
dihydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



● 2 HCl


RN 357425-87-7 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine,
7,8,9,10-tetrahydro-4-methyl-,
dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

IT 357425-88-8P 357425-89-9P 357425-90-2P
RN 357425-91-3P 357425-92-4P 357425-93-5P
RL: BAC (Biological Activity or effector, except adverse); BSU
(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl-fused azapoly cyclic compds. as nicotine binding
inhibitors)

RN 357425-88-8 CAPLUS
CN 6,10-Methano-2H-pyrido[2,3-h][3]benzazepin-2-one,
1,6,7,8,9,10-hexahydro-,
dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 357425-89-9 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine,
2-chloro-7,8,9,10-tetrahydro-,
monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



● HCl

RN 357425-93-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-, 4-
methylbenzenesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 69718-72-5
CMF C11 H13 N




CM 2

CRN 104-15-4
CMF C7 H8 O3 S




IT 230615-52-8 357426-15-357426-16-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of aryl-fused azapoly cyclic compds. as nicotine binding
inhibitors)

RN 230615-52-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-, hydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 357425-91-3 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-5-fluoro-7,8,9,10-tetrahydro-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 357425-92-4 CAPLUS
CN 6,10-Methano-2H-pyrazino[2,3-h][3]benzazepin-2-one,
1,6,7,8,9,10-hexahydro-,
monohydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




• HCl

RN 357426-15-4 CAPLUS
CN Ethioethioamide,
2,2,2-trifluoro-N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoro-
1-thioethoxyethyl)-1,5-methano-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 357426-16-5 CAPLUS
CN 5,9-Methano-5H-thiazolo[4,5-h][3]benzazepine,
6,7,8,9-tetrahydro-2-methyl-
(9CI) (CA INDEX NAME)



IT 230615-48-2P 230615-50-6P 230615-51-7P
230615-53-9P 230615-56-2P 230615-57-3P
230615-59-5P 230615-60-8P 230615-61-9P
230615-62-0P 230615-63-1P 230615-64-2P
230615-65-3P 230615-66-4P 230615-67-5P
230615-68-6P 230615-69-7P 230615-70-0P
230615-71-1P 230615-72-2P 230615-73-3P
230615-74-4P 230615-77-7P 230615-78-8P
230615-79-9P 230615-80-2P 230615-81-3P
230615-82-4P 230615-83-5P 230615-84-6P
230615-85-7P 230615-86-8P 230615-88-0P
230615-89-1P 230615-92-6P 230615-93-7P
357425-94-6P 357425-95-7P 357425-96-8P
357425-97-9P 357425-98-0P 357425-99-1P

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
357426-00-7P 357426-01-8P 357426-02-9P
357426-04-1P 357426-05-2P 357426-06-3P
357426-07-4P 357426-08-5P 357426-09-6P
357426-10-9P 357426-13-2P 357426-17-6P
357426-18-7P 357426-19-8P 357426-20-1P
357426-21-2P 357426-22-3P 357426-23-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. of aryl-fused azapolycyclic compds. as nicotine binding
inhibitors)

RN 230615-48-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 230615-50-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine,
7-fluoro-2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 230615-51-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-53-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-56-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-amine, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-57-3 CAPLUS
CN Acetamide, N-[2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 230615-59-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7,8-dinitro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-60-8 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7,8-dinitro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-61-9 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7,8-diamino-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-62-0 CAPLUS
CN 5,9-Methanimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-63-1 CAPLUS
CN 5,9-Methanimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-2-methyl-1-propyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-64-2 CAPLUS
CN 5,9-Methanimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-65-3 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-(butylamino)-1,2,4,5-tetrahydro-8-nitro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-66-4 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-amino-8-(butylamino)-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-67-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 1-butyl-5,6,8,9-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-68-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-2-methyl-1-(2-methylpropyl)-, 1,1-dimethylethyl ester


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-73-3 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-74-4 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-77-7 CAPLUS
CN 1,5-Methano-3H-3-benzazepine, 2,3,4,5-tetrahydro-7-iodo-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-78-8 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-ido-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(CA INDEX NAME)




RN 230615-69-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7,8-diamine, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-70-0 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-71-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-8-nitro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-72-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 8-amino-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-79-9 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-cyano-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-80-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-acetyl-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-81-3 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-acetyl-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-82-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)-, acetate (ester) (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-83-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-84-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 8-acetyl-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-85-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-8-[1-(hydroxymino)ethyl]-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-86-8 CAPLUS
CN 5,9-Methano-5H-1,3-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-88-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-89-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-sulfonyl chloride, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-92-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-iodo-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 230615-93-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-phenyl-3-(phenylmethyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357425-94-6 CAPLUS
CN Ethanethioamide, N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoro-1-thioxoethyl)-1,5-methano-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 357425-95-7 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 2-chloro-6,7,8,9-tetrahydro-7- (trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357425-96-8 CAPLUS
CN Boronic acid, [2,3,4,5-tetrahydro-3-(phenylmethyl)-1,5-methano-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 357425-97-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357425-98-0 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 357425-99-1 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methyl-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 357426-00-7 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-3-methyl-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357426-01-8 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 3-ethyl-7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




Aryl Fused Azapolycyclic Compounds


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357426-02-9 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine,
7,8,9,10-tetrahydro-4-methyl-
8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 357426-04-1 CAPLUS
CN Propanamide, 3,3-dimethoxy-N-[2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1,5-
methano-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 357426-05-2 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepin-2-one,
1,6,7,8,9,10-hexahydro-8-
(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357426-06-3 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine,
2-chloro-7,8,9,10-tetrahydro-


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 357426-13-2 CAPLUS
CN 1,5-Methano-2H-3-benzazepin-2-one, 1,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 357426-17-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid,
1-(2,2-dimethylpropyl)-5,6,8,9-tetrahydro-, 1,1-dimethylethyl ester,
monohydrochloride (9CI) (CA INDEX NAME)




RN 357426-18-7 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid,
1-(2,2-dimethylpropyl)-5,6,8,9-tetrahydro-2-methyl-, 1,1-dimethylethyl
ester, monohydrochloride (9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357426-07-4 CAPLUS
CN 6,10-Methano-8H-pyrido[2,3-h][3]benzazepine-8-carboxylic acid,
2-chloro-6,7,9,10-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX
NAME)



RN 357426-08-5 CAPLUS
CN 6,10-Methano-8H-pyrido[2,3-h][3]benzazepine-8-carboxylic acid,
6,7,9,10-tetrahydro-2-methoxy-, 1,1-dimethylethyl ester (9CI) (CA INDEX
NAME)




RN 357426-09-6 CAPLUS
CN 6,10-Methano-8H-pyrido[2,3-h][3]benzazepine-8-carboxylic acid,
2-chloro-5-fluoro-6,7,9,10-tetrahydro-, methyl ester (9CI) (CA INDEX
NAME)




RN 357426-10-9 CAPLUS
CN 6,10-Methano-2H-pyrazino[2,3-h][3]benzazepin-2-one,
1,6,7,8,9;10-hexahydro-

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 357426-19-8 CAPLUS
CN 6,10-Methano-8H-pyrazino[2,3-h][3]benzazepine-8-carboxylic acid,
6,7,9,10-tetrahydro-2,3-dimethyl-, 1,1-dimethylethyl ester,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 357426-20-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carboximidamide, 2,3,4,5-tetrahydro-N-
hydroxy- (9CI) (CA INDEX NAME)




RN 357426-21-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-[3-(dimethylamino)-1-oxo-2-propenyl]-
2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)

Aryl Fused Azapoly(cyclic Compounds)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 357426-22-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N,N-dimethyl-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 357426-23-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(1-pyrrolidinylsulfonyl)-3-(trifluoroacetyl)-, monohydrochloride (9CI) (CA INDEX NAME)



• HCl

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L22 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001152263 CAPLUS
DOCUMENT NUMBER: 134198095
TITLE: Composition for the treatment and prevention of nicotine addiction containing a nicotine receptor agonist and an anti-depressant or anti-anxiety drug
INVENTOR(S): Coe, Jotham Wadsworth; Harrigan, Edmund Patrick; O'neill, Brian Thomas; Sanda, Steven Bradley
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 18 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

	KIND DATE	APPLICATION NO. DATE
ED 1078637	A2 20010228	EP 2000-307254 20000823
EP 1078637	A3 20030305	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, PL, RO		
JP 2001072604	A2 20010321	JP 2000-254041 20000824
ZA 2000004406	A 20020225	ZA 2000-4406 20000825
US 2003109544	A1 20030612	US 2003-348399 20030121
PRIORITY APPLN. INPO.: US 1999-151089P P 19990827		
		US 2000-578369 B1 20000525
		US 2000-697749 A1 20001026


AB Pharmaceutical compds. are disclosed for the treatment of nicotine dependence or addiction, tobacco dependence or addiction, reduction of nicotine withdrawal symptoms or aiding in the cessation or lessening of tobacco use or substance abuse. The pharmaceutical compds. are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an anti-depressant or anxiolytic agent and a pharmaceutically acceptable carrier. The method of using these compds. is also disclosed.

IT 69718-72-5	230615-75-5	349296-44-4
287973-26-6	328055-77-2	328055-78-3
328055-79-4	328055-80-7	328055-81-8
328055-82-9	328055-83-0	328055-84-1
328055-85-2	328055-86-3	328055-87-4
328055-88-5	328055-89-6	328055-90-9
328055-92-1	328055-93-2	328055-94-3
328055-95-4	328055-96-5	328055-97-6
328055-98-7	328055-99-8	328056-66-2
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (nicotine and other drug addiction treatment with compds. containing nicotine receptor agonists and antidepressants or anxiolytic agents)		
RN 69718-72-5 CAPLUS		
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)		




L22 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 230615-75-5 CAPLUS
CN 5,9-Methanocyclo[4.5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 249296-44-4 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)



RN 387973-26-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-difluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-77-2 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 328055-78-3 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)

L22 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 328055-79-4 CAPLUS
CN 5,9-Methanocyclo[4.5-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 328055-80-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-81-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-ethynyl-8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-82-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-ethynyl-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-83-0 CAPLUS

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN 5,9-Methano-2H-isothiazolo[4,5-h][3]benzazepine, 3,5,6,7,8,9-hexahydro-2-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 328055-84-1 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)



RN 328055-85-2 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 328055-86-3 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro- (9CI) (CA INDEX NAME)




RN 328055-87-4 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl- (9CI) (CA INDEX NAME)


L22 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-88-5 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 328055-89-6 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl- (9CI) (CA INDEX NAME)




RN 328055-90-9 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl- (9CI) (CA INDEX NAME)




RN 328055-92-1 CAPLUS
 CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl- (9CI) (CA INDEX NAME)


L22 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-93-2 CAPLUS
 CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepine, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 328055-94-3 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-95-4 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-96-5 CAPLUS
 CN Ethanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)



RN 328055-97-6 CAPLUS
 CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



Aryl Fused Azapolycyclic Compounds

L22 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:553442 CAPLUS

DOCUMENT NUMBER: 133:168383

TITLE: Pharmaceutical compositions containing nicotine or a ligand of nicotine receptors and a monamine oxidase inhibitor and their use for treating tobacco withdrawal symptoms

INVENTOR(S): Caillie, Dominique; George, Pascal; Jegham, Samir; Robinet, Pascale; Scatton, Bernard; Zivkovic, Branimir

PATENT ASSIGNEE(S): Sanofi-Synthelabo, Pr.

SOURCE: PCT Int. Appl., 37 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000045846	A1	20000910	WO 2000-FR193	20000128
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, ES, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MD, MO, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, PR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BE, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2788982	A1	20000804	FR 1999-1144	19990202
FR 2788982	B1	20020402		
EP 1150715	A1	20011107	EP 2000-901660	20000128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002536342	T2	20021029	JP 2000-596965	20000128
PRIORITY APPLN. INFO.:			FR 1999-1144	A 19990202
			WO 2000-FR193	W 20000128

OTHER SOURCE(S): MARPAT 133:168383

AB The invention concerns novel pharmaceutical compns. containing nicotine or a ligand of nicotine receptors and a monamine oxidase inhibitor designed for

treating tobacco withdrawal symptoms. A bilayer tablet contained beflexatone 5, lactose 66, microcryst. Cellulose 20, povidone 4, crospovidone 4, and magnesium stearate 1% in the first layer, and nicotine

polarcrelles 5, microcryst. cellulose 20 povidone 4, hydroxypropyl Me cellulose 25, magnesium stearate 1, and lactose q.s. 100% in the second layer.


IT 287973-24-4 287973-25-5 287973-26-6

287973-27-7 287973-28-8 287973-29-9


287973-32-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES


L22 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 287973-28-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro-8-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 287973-29-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro-8-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 287973-32-4 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepine-1,3(2H,5H)-dione, 5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE


FORMAT

L22 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


(Uses) (pharmaceutical compns. contg. nicotine or ligand of nicotine

receptors and monamine oxidase inhibitor and their use for treating tobacco withdrawal symptoms)


RN 287973-24-4 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepine-1,3(2H,5H)-dione, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 287973-25-5 CAPLUS
CN 5,9-Methanimidazo[4,5-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 287973-26-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-difluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 287973-27-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-ethynyl-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

ACCESSION NUMBER: 1999:451282 CAPLUS

DOCUMENT NUMBER: 131:102204

TITLE: Preparation of 1,5-methano-3-benzazepines and analogs as nicotinic receptor ligands

INVENTOR(S): Coe, Jotham Wadsworth; Brooks, Paige Roanne Palmer

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 83 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9935131	A1	19990715	WO 1998-IB1813	19981113
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TU, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, PR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2316921	AA	19990715	CA 1998-2316921	19981113
AU 9896416	A1	19990726	AU 1998-96416	19981113
AU 753389	B2	20020107		
BR 9814592	A	20000107	BR 1998-14592	19981113
EP 1044189	A1	20000108	EP 1998-950274	19981113
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IR, SI, LT, IV, FI, RO				
TR 200001840	T2	20001221	TR 2000-200001840	19981113
JP 2002500218	T2	20020108	JP 2000-527532	19981113
NZ 504482	A	20030131	NZ 1998-504482	19981113
TW 513412	B	20021211	TW 1998-87121748	19981228
ZA 9811911	A	20000629	ZA 1998-11911	19981229
US 6410550	B1	20020625	US 1999-402010	19990928
US 6605610	B1	20030812	US 2000-514002	20000225
DE 1005611	A	20010131	DE 2000-104561	20000227
NO 2000030422	A	20000429	NO 2000-322	20000310
HR 2000000445	A1	20010430	HR 2000-445	20000630
US 6400072545	A1	20000413	US 2002-7584	20020213
US 2000072524	A1	20000613	US 2002-7518	20020214
US 2002111350	A1	20020815	US 2002-132267	20020422
US 2002132624	A1	20020919	US 2004-131278	20030423
US 2003130261	A1	20030710	US 2004-336508	20030103
US 2003130260	A1	20030710	US 2003-336532	20030103
PRIORITY APPLN. INFO.:			US 1998-702451	P 19971231
			WO 1998-1B1813	W 19981113
			US 1999-402010	A2 19990928
			US 2000-514002	A1 20000225

OTHER SOURCE(S): MARPAT 131:102204 GI

Aryl Fused Azapolycyclic Compounds

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB Title compds. [I; R1 = H, alk(en)yl, alkoxyethyl, oxoalkyl, etc.; R2,R3 = H, halo, (alkyl)amino, alkyl, etc.; R2R3 = atoms to complete a ring] were prepared. Thus, 2-FC6H4Br was cyclocondensed with cyclopentadiene and the product esterified to give 1,2,3,4-tetrahydro-1,4-methanonaphthalene-2,3-diol which was treated with NaIO4 and the product cyclocondensed with PhCONHNH2 to give, after deprotection, I (R1-R3 = H). Data for biol. activity will be given.

IT 69718-72-5 230614-99-0 230615-00-6P

230615-01-7P 230615-02-8P 230615-03-9P

230615-04-0P 230615-05-1P 230615-06-2P

230615-07-3P 230615-08-4P 230615-09-5P

230615-10-8P 230615-11-9P 230615-12-0P

230615-13-1P 230615-14-2P 230615-15-3P

230615-16-4P 230615-17-5P 230615-18-6P

230615-19-7P 230615-20-8P 230615-21-1P

230615-22-2P 230615-23-3P 230615-24-4P

230615-25-5P 230615-26-6P 230615-27-7P

230615-28-8P 230615-29-9P 230615-30-2P

230615-31-3P 230615-32-4P 230615-33-5P

230615-34-6P 230615-35-7P 230615-36-8P

230615-37-9P 230615-38-0P 230615-39-1P

230615-40-4P 230615-41-5P 230615-42-6P

230615-43-7P 230615-44-8P 230615-45-9P

230615-46-0P 230615-52-8P 230615-75-5P

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of 1,5-methano-1H-benzazepines and analogs as nicotinic receptor ligands)

RN 69718-72-5 CAPLUS

CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 230614-99-0 CAPLUS


CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-00-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-01-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-02-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



● HCl

RN 230615-03-9 CAPLUS


CN 1,5-Methano-1H-3-benzazepine, 6-fluoro-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-04-0 CAPLUS

CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-05-1 CAPLUS


CN 1,5-Methano-1H-3-benzazepin-7-amine, 2,3,4,5-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-06-2 CAPLUS
CN Acetamide, N-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-07-3 CAPLUS
CN 5,9-Methano-5H-thiazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-08-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7,8-dinitro- (9CI) (CA INDEX NAME)



RN 230615-09-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
propyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-10-8 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-11-9 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-12-0 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-13-1 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-14-2 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-15-3 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-butyl-1,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-16-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-17-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-18-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-19-7 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-20-0 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-1,5,6,7,8,9-hexahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-21-1 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-22-2 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-, 1,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-23-3 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-24-4 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-28-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-29-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-30-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(5-methyl-1,2,4-oxadiazol-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-25-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-26-6 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-27-7 CAPLUS
CN Benzamide, 2-fluoro-N-(2,3,4,5-tetrahydro-8-hydroxy-1,5-methano-1H-3-benzazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-31-3 CAPLUS
CN Ethanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-32-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-33-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-34-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine,
2,3,4,5-tetrahydro-7-(1-methyl-1H-pyrazol-5-
yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-35-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine,
2,3,4,5-tetrahydro-7-(1-methyl-1H-pyrazol-5-
yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-36-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro-,
hydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-37-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-38-0 CAPLUS
CN Pyrrolidine, 1-[2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl]sulfonyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-39-1 CAPLUS
CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro-,
monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-40-4 CAPLUS
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one, 3,5,6,7,8,9-hexahydro-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-41-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-phenyl-, hydrochloride
(9CI) (CA INDEX NAME)



● HCl


RN 230615-42-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-6-ol, 2,3,4,5-tetrahydro-, hydrochloride
(9CI) (CA INDEX NAME)

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-43-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-difluoro-2,3,4,5-tetrahydro-,
hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-44-8 CAPLUS
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepine, 2-ethyl-6,7,8,9-tetrahydro-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-45-9 CAPLUS
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-46-0 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-52-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-75-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)


L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




IT 230615-48-2P 230615-50-6P 230615-51-7P
230615-53-9P 230615-54-0P 230615-55-1P
230615-56-2P 230615-57-3P 230615-58-4P
230615-59-5P 230615-60-6P 230615-61-9P
230615-62-0P 230615-63-1P 230615-64-2P
230615-65-3P 230615-66-4P 230615-67-5P
230615-68-6P 230615-69-7P 230615-70-0P
230615-71-1P 230615-72-2P 230615-73-3P
230615-74-4P 230615-76-6P 230615-77-7P
230615-78-8P 230615-79-9P 230615-80-2P
230615-81-3P 230615-82-4P 230615-83-5P
230615-84-6P 230615-85-7P 230615-86-8P
230615-87-9P 230615-88-0P 230615-89-1P
230615-90-4P 230615-92-6P 230615-93-7P
230615-94-8P 230615-95-9P

RL RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 1,5-methano-3-benzazepines and analogs as nicotinic receptor ligands)

RN 230615-48-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 230615-50-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine,
7-fluoro-2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 230615-51-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-53-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-54-0 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid,
1,2,4,5-tetrahydro-7-nitro-
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-55-1 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid,
7-amino-1,2,4,5-tetrahydro-
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-56-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-amine, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-57-3 CAPLUS
CN Acetamide, N-[2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 230615-58-4 CAPLUS
CN Ethanethioamide,
N-[2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 230615-59-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7,8-dinitro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-60-8 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7,8-dinitro-
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-61-9 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7,8-diamino-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-62-0 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-63-1 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-2-methyl-1-propyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-64-2 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid,


L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-2-methyl-1-(2-methylpropyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-69-7 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-7,8-diamine, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-70-0 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-71-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-8-nitro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-72-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 8-amino-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
5,6,8,9-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-65-J CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-(butylamino)-1,2,4,5-tetrahydro-8-nitro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-66-4 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-amino-8-(butylamino)-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-67-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 1-butyl-5,6,8,9-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-68-6 CAPLUS


L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-73-3 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-74-4 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-76-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-77-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-jodo-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 21 OF 23 CAPIUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-78-8 CAPIUS
CN 1,5-Methano-1H-3-benzazepine-3-carboxylic acid,
1,2,3,4,5-tetrahydro-7-iodo-
, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-79-9 CAPIUS
CN 1,5-Methano-1H-3-benzazepine-3-carboxylic acid,
7-cyano-1,2,4,5-tetrahydro-
, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-80-2 CAPIUS
CN 1,5-Methano-1H-3-benzazepine, 7-acetyl)-2,3,4,5-tetrahydro-3-
(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-81-3 CAPIUS
CN 1,5-Methano-1H-3-benzazepine-3-carboxylic acid, 7-acetyl-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L22 ANSWER 21 OF 23 CAPIUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-82-4 CAPIUS
CN 1,5-Methano-1H-3-benzazepin-7-ol,
2,3,4,5-tetrahydro-3-(trifluoroacetyl)-,
acetate (ester) (9CI) (CA INDEX NAME)



RN 230615-83-5 CAPIUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)-
(9CI) (CA INDEX NAME)




RN 230615-84-6 CAPIUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 8-acetyl-2,3,4,5-tetrahydro-3-
(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-85-7 CAPIUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-8-[1-
(hydroxymino)ethyl]-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 21 OF 23 CAPIUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-86-8 CAPIUS
CN 5,9-Methano-5H-1,3-benzodiazepolo[4,5-h][3]benzazepine,
6,7,8,9-tetrahydro-3-methyl-
7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-87-9 CAPIUS
CN 1,5-Methano-1H-3-benzazepine-7-propanamine, 2,3,4,5-tetrahydro-N,N-dimethyl-γ-oxo-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-88-0 CAPIUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-89-1 CAPIUS
CN 1,5-Methano-1H-3-benzazepine-7-sulfonyl chloride, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 21 OF 23 CAPIUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-90-4 CAPIUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(1-pyrrolidinylsulfonyl)-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-92-6 CAPIUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-iodo-3-(phenylmethyl)-
(9CI) (CA INDEX NAME)




RN 230615-93-7 CAPIUS
CN 1,5-Methano-1H-3-benzazepine,
2,3,4,5-tetrahydro-6-phenyl-3-(phenylmethyl)-
(9CI) (CA INDEX NAME)




RN 230615-94-8 CAPIUS
CN Boronic acid, [2,3,4,5-tetrahydro-3-(phenylmethyl)-1,5-methano-1H-3-benzazepin-6-yl]- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 230615-95-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-6-ol, 2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

PATENT NO.		KIND	DATE	APPLICATION NO.	DATE
EP 286263	A1	19881012	EP 1988-302499	19880322	
EP 286263	B1	19910515			
R: AT, BE, CH, DE, ES, FR, GR, IT, LI, LU, NL, SE					
US 4797488	A	19890110	US 1987-34820	19870403	
CA 1306251	A1	19920811	CA 1988-561882	19880318	
GB 2203428	A1	19881019	GB 1988-6778	19880322	
GB 2203428	B2	19901031			
AT 63551	E	19910615	AT 1988-302499	19880322	
ES 2039617	T3	19931001	ES 1988-302499	19880322	
AU 8813512	A1	19881006	AU 1988-13512	19880323	
AU 597480	B2	19900531			
WO 8807529	A1	19881006	WO 1988-US973	19880331	
W: DK, JP, KR					
JP 01502756	T2	19890921	JP 1988-503414	19880331	
US 4824999	A	19890425	US 1988-248769	19880923	
DK 8806738	A	19881202	DE 1988-6738	19881202	
AU 9051158	A1	19900628	AU 1990-51158	19900308	
AU 617930	B2	19911205			
PRIORITY APPLN. INFO.:			US 1987-34820	19870403	
			EP 1988-302499	19880322	
			WO 1988-US973	19880331	
OTHER SOURCE(S):	CASREACT 111:23537; MARPAT 111:23537	GI			

L22 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB The title compda. [I: R = (halo)-2-pyrimidinyl, (halo)pyrazinyl, (halo)quinolinyl, (un)substituted Ph, pyridinyl; R1R2 = C3-5 alkylene, C3-5 alkenylene, polycyclic alkanediyl moiety Q. Q1, atoms to complete a fused benzo ring; X = R3R4C, S, SO, SO2; R3, R4 = H, Cl-4 alkyl; R3R4 = C2-4 alkenylene; Y = CH2, CH2CH2, O, S; n = 2-5; dotted line represents optional double bond] and their pharmaceutically acceptable salts were prepared as psychotropic agents, useful as antipsychotics and anxiolytics.

Bicyclo[3.3.0]octane-2,4-dicarboxylic acid was refluxed 3 h in Ac2O to give its anhydride which was refluxed 48 h with 1-(4-aminobutyl)-4-(trifluoromethyl)piperazine in xylene to give, after acidification, methanocyclopentazepinedione II. In rats, II inhibited the conditioned avoidance response with an ED50 of 46.17 mg/kg orally and inhibited apomorphine-induced stereotypy and climbing behavior with ED50 of 42.37 and 18.89 mg/kg orally, resp.


IT 121305-54-2P 121305-55-3P 121305-69-9P

RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (preparation of, as antipsychotic)


RN 121305-54-2 CAPLUS

CN 1,5-Methano-1H-3-benzazepine-2,4(3H,5H)-dione, 3-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)


L22 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 121305-55-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-2,4(3H,5H)-dione, 3-[4-[4-(6-chloropyrazinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)



RN 121305-69-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-2,4(3H,5H)-dione, 3-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- dihydrochloride (9CI) (CA INDEX NAME)




•2 HCl

RN 121305-70-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-2,4(3H,5H)-dione, 3-[4-[4-(6-chloropyrazinyl)-1-piperazinyl]butyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapoly cyclic Compounds

L22 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



● HCl

L22 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1979:432639 CAPLUS
 DOCUMENT NUMBER: 91:32639
 TITLE: Synthesis and pharmacological activity of 2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepines
 AUTHOR(S): Mazzocchi, Paul H.; Stahly, Barbara C.
 CORPORATE SOURCE: Dep. Chem., Univ. Maryland, College Park, MD, USA
 SOURCE: Journal of Medicinal Chemistry (1979), 22(4), 455-7
 CODEN: JMCAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 91:32639
 GI



AB The title compds. I (R = H, alkyl, allyl, etc.) were prepared from 2,3-dioxobenzonorbornene. 3-Allyl-2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepine oxalate (1:1) showed a slight antinociceptive activity in the mouse hot-plate assay and little antagonistic activity in the tail-flick assay. None of other I showed significant analgesic activity and all except 2,3,4,5-tetrahydro-3-(2-phenylethyl)-1,5-methano-1H-3-benzazepine oxalate (1:1) were toxic. Structure-activity relations are discussed.

IT 69718-72-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and alkylation of)
 RN 69718-72-5 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



IT 69718-73-6P 69718-78-1P 69718-80-5P
 69718-83-8P 69718-85-0P 69718-87-2P
 69718-89-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and analgesic and narcotic antagonist activities of)
 RN 69718-73-6 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 69718-72-5
 CMF C11 H13 N

L22 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




CM 2
 CRN 144-62-7
 CMF C2 H2 O4



RN 69718-78-1 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-methyl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1
 CRN 69718-77-0
 CMF C12 H15 N

L22 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2


CRN 144-62-7
 CMF C2 H2 O4



RN 69718-83-8 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 69718-82-7
 CMF C15 H19 N



CM 2

CRN 144-62-7
 CMF C2 H2 O4




RN 69718-85-0 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-propyl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 69718-84-9
 CMF C14 H19 N

Aryl Fused Azapolycyclic Compounds

L22 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 69718-87-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-(2-propenyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 69718-86-1
CMF C14 H17 N



CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 69718-89-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-(3-methyl-2-butenyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 69718-88-3
CMF C16 H21 N


L22 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 69718-84-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-propyl- (9CI) (CA INDEX NAME)



L22 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




CM 2


CRN 144-62-7
CMF C2 H2 O4



IT 69718-76-9P 69718-81-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)
RN 69718-76-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-2,4(3H,5H)-dione (9CI) (CA INDEX NAME)



RN 69718-81-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 3-(cyclopropylcarbonyl)-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



IT 69718-77-0P 69718-84-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 69718-77-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)